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Abstract 
Autosomal dominant retinitis pigmentosa (ADRP) is the most common genetic 
disorders which cause visual degradation, and blindness. 20-25% of cases are caused 
by mutations in the rhodopsin gene. The mutations located in the N-terminus of 
rhodopsin produce severely misfolded protein, which has been shown to cleave at the 
N-terminus removing the glycosylation sites (Tam & Moritz, 2007), (Krebs, et al., 
2010). We aimed to further understand the pathology of retinitis pigmentosa by 
separating full rhodopsin from the truncated rhodopsin of the mutant, and we 
constructed rhodopsin N-terminus ADRP mutations: T4K, P23A/H and Q28H. Wild 
Type and mutant rhodopsin were purified using 1D4-sepharose separation. Our 
results supported papers indicating P23A and T4K show lowest degrees of misfolding. 
Assuming the glycosylation sites are removed we attempted to isolate the truncated 
species of the ADRP mutant by Con A-Sepharose which binds to the glycan moieties 
extended from the glycosylation sites N2 and N15 (De Grip, W. J.,1982). We isolated 
purified ROS rhodopsin and full P23A rhodopsin. We failed to isolate the P23A 
truncated species, and poor binding was apparent from full rhodopsin in the wash and 
flow through after binding. Meaning the truncated species if present would not have 
been isolated. Further alterations are needed to make the Con A-sepharose 
separation successful. 
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Chapter 1) Literature review  
1.1 The Structure of the Retina: with focus on the pathway of light and how this 
leads to vision. 
The retina is a small plate of cells that lies at the back of the eye. It is 0.2 mm-0.5 mm 
thick and 30-40 mm in diameter and is comprised of central nervous tissue (Sung & 
Chuang, 2010) (Hubel, 2009)(Kolb, 2005). It consists of 6 main layers; retinal pigment 
epithelium (“RPE”), photoreceptors, horizontal cells, bipolar cells, amacrine cells, and 
ganglion cells. These cells/neurons together work to take a photon of light and convert 
it to a neuronal signal the brain can transform into a clear image of the world we see 
around us (Reminington, 2011). This system is very delicate and even the slightest 
alteration can cause a system failure.  
The RPE is the cell layer that lies furthest from the point of light entry,  followed by the 
photoreceptors which are so turned that the apical side faces the RPE (Sung & 
Chuang, 2010). The RPE is a monolayer of hexagonal cells, that forms part of the 
blood/ brain barrier (Strauss, 2005) and has many functions that are necessary for the 
visual pathway, these include: phagocytosis of POS (photoreceptors outer segment) 
in which 10% of volume is shed (Kevany & Pakczewski, 2012); the regeneration of 11-
cis-retinal from all-trans-retinal; removal of excess and scattered light; protection of 
the retina from oxidative stress and is required for the removal and delivery of multiple 
ions and proteins.   
To facilitate this transport and phagocytosis it has microvilli that extend from its apex 
membrane and wrap around the outer segment of photoreceptors. There are two types 
of microvilli; the longer microvilli are used for transport of glucose, retinol and fatty 
acids from the blood whereas the shorter microvilli form photoreceptor sheaths which 
help with phagocytosis of POS (Strauss, 2005). The essential products from the 
reaction, such as retinal, are recycled back to the photoreceptors for outer segment 
regeneration (Strauss, 2005). The RPE contains various pigments, including that of 
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melanin which is hypothesised to “mop up” any remaining light that is not absorbed by 
the photoreceptors, stopping the light from rebounding back. Providing a possible 
reason as to why the eye has developed in an inversed manner (Hubel, 2009). The 
RPE is also partly responsible for the regeneration of photoreceptors after bleaching 
(Strauss, 2005).  
There are two types of photoreceptors, rods and cones. Rods mediate vision in dimly 
lit areas and in the periphery while cones are needed for bright light, and colour. Rod 
cells while highly sensitive have a low photon saturation, whereas cones are opposite 
in this respect (Kevany & Pakczewski, 2012). They are so called due to their shapes, 
while rods tend to be long and thin, cones are short and conical (Hubel, 2009). There 
are many more rods than cones with rods outnumbering cones 20 fold at  about 130 
million cells per retina (Sung & Chuang, 2010) (Masland, 2001). The rod cells are 
found in greater number towards the periphery of the cell however, the cones are found 
closer to the centre. The fovea, the central region of the retina where fine detail is best 
contains only cones which are densely packed. The fovea is central to vision and within 
this pit of the retina the light has a direct path from the pupil to the photoreceptor, as 
the other neurons have been pushed to the side (Hubel, 2009) (Sung & Chuang, 2010). 
This allows for a clearer, sharper, centre of vision. The main function of the 
photoreceptors is to absorb photons of light, via their opsin. Each photoreceptor has a 
different opsin, this protein in rod cells is named rhodopsin and will be discussed in 
below. This opsin once stimulated by the photon undergoes a process called 
phototransduction and sends a signal either to the bipolar cells or the horizontal cells. 
In darkness photoreceptor cells are constantly secreting glutamate and only stop 
secretion once a photon of light has been absorbed and the cell has been stimulated. 
This constant secretion of the neurotransmitter means the horizontal cells are also 
stimulated at all times. Once the photon of light has been absorbed, the glutamate is 
no longer secreted causing the cell to hyperpolarise. There are two types of orizontal 
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cells, with two functions; to pass on the neuronal signal to bipolar cells, and lateral 
inhibition. Lateral inhibition occurs when the cell inhibits distant photoreceptors in its 
visual field to increase vision acuity (Masland, 2001) (Masland, 2012). The outcome is 
areas of light increase in brightness and areas of darkness become even darker 
leading to a clearer, sharper image (Thoreson, et al., 2008).  
Bipolar cell dendrites synapse with photoreceptor terminals and horizontal cells 
(William, 2005), whilst its single axon synapses with ganglion cells and amacrine cells 
(Snell & Lemp, 1998). Bipolar cells have been classed on the basis of morphology, 
physiology, and dendritic contacts with photoreceptors, to reveal 12 types (Masland, 
2012) (Reminington, 2011).  Only one of these is a rod bipolar cell, the rod bipolar cell 
has a large cell body and several spike-like dendrites; these are the only bipolar cells 
which synapse with rod cells. As the retina evolved the rod photoreceptors also 
evolved transforming from cone photoreceptors leaving causing them to “piggyback” 
on the already ‘in place’ system (Masland, 2001). One rod bipolar cell’s dendrites can 
contact between 15-20 rod photoreceptors in the central retina and up to 80 rod 
photoreceptors in the periphery, thereby improving sensitivity. A rod bipolar cell 
interacts with more rod photoreceptors than a cone bipolar cells interacts with cone 
photoreceptors, meaning that  more cone bipolar cells are required in the retina 
(Masland, 2001).  This is seen in the case of  invagination midget bipolar cells, which 
connect a signal cone cell to a single ganglion cell (Snell & Lemp, 1998) (William, 
2005). The rod bipolar axon mainly contacts amacrine cells and very rarely contacts 
ganglion cells directly (Masland, 2001). This is to enable ganglion cells to carry 
information from both rod and cone cells (Reminington, 2011). 
 The ganglion cells have a diameter between 10-30 µm, and in most of the retina are 
a single layer. They are multipolar as their dendrites have the ability to synapse with 
both bipolar and amacrine cells. There are two types of ganglion cells: diffuse ganglion 
cells, and midget ganglion cells. The midget ganglion cell has one dendrite and 
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connects to either an invagination ganglion cell, or a flat midget ganglion cell, which 
might be linked to only one photoreceptor. This is likely to occur in the fovea where a 
single ganglion cell receives input from a single cone (Masland,2001) and again is 
used to enhance contrast detail and colour resolution (Reminington, 2011).  Ganglion 
cell axons converge together at the optic disc to create the optic nerve. (William, 2005). 
The photon of light passes from the photoreceptors through the pathway of neurons 
and finally to the ganglion cells which are present in the optic nerve, during this journey 
the light signal is converted to an electric signal which enables the brain to form an 
image of the world we see around us. The eye is one of the most complicated set of 
neurons found in the human body and  one of the oldest, it is extremely sensitive to 
change, and failure of any of the neurons can lead to loss of vision.  
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Figure 1 Basic structure of the mammalian retina. The diagram depicts the 
structure of the neurons and cells found within the retina. The Photon of light is 
absorbed by the photoreceptors, where, during photo transduction, it is turned 
into an electrical impulse. This impulse travels through the bipolar cells with the 
horizontal cells either acting as an indirect pathway or as a method to increase 
visual acuity. The impulse passes onto the ganglion cells, and to the brain where 
an image is formed. The amacrine cells again are used as an indirect pathway 
but have multiple different functions including inhibitory function. The muller Glia 
cells are used to aid functional and structural stability. This image was adapted 
from (LifeMap Sciences, 2019). 
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1.2 The structure of The Rod Photoreceptor with respect to movement of 
rhodopsin  
Rod photoreceptors are highly sensitive and are needed for dim light conditions. There 
are 120 million rod cells in the human retina. The rod cells lie adjacent to the RPE and 
are vital for the survival of photoreceptors which are 40-60 µm long and 1.5-3 µm wide 
(William, 2005) (Molday & Moritz, 2015). The rod cells  are long and thin in shape with 
a slight bulge in the cell body where the nucleus lies (William, 2005). It is formed of 
multiple sections; the outer segment (“OS”), the connecting cilium (“CC”), the inner 
segment (“IS”), cell body or nuclear region and the synaptic region or rod spherule. 
The OS has a length of 30-60 µm and diameter 1.4-10 µm (depending on the 
species),and is filled with 600 - 1,000 flattened lamella shaped membrane discs (Sung 
& Chuang, 2010) (Reminington, 2011).  Each of these discs are 2 µm in diameter, 
about 14 nm thick (Snell & Lemp, 1998), and are bridged by filamentous structures 
(Sung & Chuang, 2010). Rhodopsin, the GPCR photopigment, is incoporated into 
these discs upon their synthesis, at the base of the OS making up 95 % of the protein 
present (Sung & Chaung, 2010). The OS undergoes phagocytosis by the RPE in a 
removal and replacement cycle which lasts twenty four hours. Thus the rod cell is 
constantly sythesising new discs and new rhodopsin (Mcdevitt, 2012) (Kevany & 
Pakczewski, 2012). High density of rhodopsin, and ordered alignment with respect to 
light path, increases the probability of capturing a photon of light (Sung & Chuang, 
2010).  
The CC, connects the IS to the OS and allows for the passage of proteins (Molday & 
Moritz, 2015). Permitting them to run continuously through a narrow cylindrical stalk 
originating in the inner segment, it contains a modified cilium. This cilium has the 
standard nine double microtubule structure but lacks the central pair. The apical 
surface forms a ridge like structure that surrounds the CC circumference. The apical 
ridge is opposed to the basal OS (Sung & Chuang, 2010). Rhodopsin is trafficked to 
12 
 
the OS via the CC. It is believed rhodopsin has trafficking signals located on the c-
terminus that help to direct the protein to the OS; this is a complicated system and its 
failure leads to many different retinal dystrophies (Nemet, et al., 2015). This trafficking 
of the rhodopsin molecule can be affected by the mutations that occur on the Rho 
gene. The trafficking system is very sensitive and relies on the correct folding of the 
protein so that it can be properly incorporated into the OS. The formation of poorly 
folded or misfolded proteins can lead to incorrect formation of the OS. 
The IS can be thought of as comprised of two sections; ellipsoid and myoid. Ellipsoid 
is the closest to the OS and contains abundant mitochondria. Myoid contains the ER 
and the Golgi, and is the site of metabolism, biosynthesis, and endocytosis. The opsin 
which binds the chromophore to form rhodopsin is manufactured in the myoid of the 
inner segment before it is trafficked up and into the OS via the CC. The IS is connected 
to the cell body or nuclear region via the outer fibre which is about 1 µm wide 
(Reminington, 2011). The cell body contains the nucleus, which is the site of 
transcription. The inner fibre, contains many microtubules, it connects the cell body to 
the spherule (also known as the synaptic terminal) which contains the synaptic 
vesicles and synaptic ribbon (William, 2005). The rod spherules are the site of the 
synaptic contact between horizontal and bipolar cells (Li, et al., 2016) (Snell & Lemp, 
1998) (William, 2005). This will be where the electrical signal is first fired to kick-start 
the process of vision.  
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Figure 2 Basic structure of the mammalian rod photoreceptor. This is a 
schematic diagram of a rod photoreceptor fully annotated, showing the outer 
segment connected via the connecting cilium to the inner segment which allows for 
the trafficking of proteins. Clearly showing the difference between the two sections 
of IS; elipsoid containing only mitochondria closer to the OS and the Myoid which 
contains the ER and Golgi apparatus. This was adapted from (Cote, 2006). 
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1.3 The structure of rhodopsin with focus on the extracellular domain and the 
changes caused by activation. 
Located in the OS, rhodopsin is the most abundant protein within the rod photoreceptor, 
responsible for scotopic vision, it is formed of opsin and 11-cis-retinal within the human 
retina. Rhodopsin is a GPCR, part of the A family. It is the best characterised GPCR 
that exists due to the easily accessible rhodopsin in bovines. Rhodopsin has the 
classic conserved 7 alpha helical transmembrane structure. However, unlike most 
GPCRs rhodopsin is constantly bound to its ligand 11-cis-retinal in both dark inactive 
states, and after phototransduction (Bourne & Meng, 2000). Rhodopsin functions to 
convert a light signal to an electrical signal, that can be used to form an image of the 
world around us, by absorbing a photon of light which triggers] the phototransduction 
cascade. 
Rhodopsin is comprised of 348 amino acids and can be roughly distinguished by 
region: extracellular domain, intracellular domain, and membrane domain. The 
extracellular domain is composed of three extracellular loops (E1-E3), and the N-
terminus, the intercellular domain is made up of three cytoplasmic loops (C1-3) and 
the C-terminus and the membrane domain is made up of 7α helices (Palczewski, et 
al., 2000).  
The N-terminus consists of 5 distorted strands. The first two strands between the loci 
Gly3 to Pro12 are betta sheets and run parallel to the membrane. The other three 
strands form a right triangle between Phe13 to Pro34   with the third, strand 3 runs below 
the third extracellular loop, and the fourth strand connects Ser14 – Asn15 with Pro23 
located close to the 1st extracellular loop (Palczewski, et al., 2000). The 
oligosaccharide chains which extend from Asn2 and Ans15 attached during 
glycosylation do not have any interactions with rhodopsin and it has been suggested 
they could maintain orientation between E1 and N-terminal domains. Further evidence 
indicates the N-terminal domain remains static during activation, and that mutations 
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effecting glycosylation (T4K and T17M) have led to movement of this domain and thus 
instability of the protein. With one paper suggesting that the oligosaccharides may 
stabilise the molecule via steric hindrance and stabilising interactions (Tam, et al., 
2014). 
In the ground state 11-cis-retinal is bound at the Lys296 via a protonated Schiff base. 
The stability of this state is ensured by the Schiff base network which is made up of 
residues in the E2 loop, a hydrogen bond network, water molecules and the protonated 
Schiff base which forms a salt bridge with counterion Glu113 (Hofmann, et al., 2009). It 
is further stabilised by constraint tethers of TM3 and TM5 by a hydrogen bonding 
network which includes the use of Glu 222, Trp126 and His211. In large part Rhodopsin 
follows the general structure found in GPCRs with differences found in the ligand 
binding site, and the structural domain, designed to shield the hydrophobic retinal 
ligand from the aqueous phase (Hofmann, et al., 2009). The Ionic lock which stabilizes 
the inactive state is formed by the cytoplasmic network between E(D)RY motif on H3 
and H6, which upon activation is removed (Vogel, et al., 2008). This Ionic lock includes 
Glu247 and Glu249 on H6, which are thought to form hydrogen bonds and ionic 
interactions with Glu134 and Arg135 on H3, and interhelical interactions with H7 (Vogel, 
et al., 2008) (Hofmann, et al., 2009) (Palczewski, et al., 2000). An additional structural 
motif present in inactive rhodopsin is NP xxY(X)F motif which is present on the TM7-
H8 (Hofmann, et al., 2009). 
Rhodopsin when subject to light undergoes a conformational change to active 
conformation, metarhodopsin II; it is in this conformation that rhodopsin binds G-
protein transducin (Marin, et al., 2000). This leads to structural changes to the H6/H7 
interface, the breakdown of the E(D)RY motif via protonation of Glu134   ,and the 
breakdown of the ionic lock and NP xxY(X)F motif, which allows formation of new 
interactions (Vogel, et al., 2008) (Hofmann, et al., 2009). Changes are found in TM5 
which is extended by 1.5-2.5 helix turns and moves 2-3 A towards TM6. TM6 also 
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shows changes tilting outwards from the helix bundle by 6-7 A.  These structural 
changes form a crevice in the cytoplasmic side of the receptor (Hofmann, et al., 2009).  
This crevice enables the binding of the transducin G protein. 
It is known that the binding site for transducin is on the cytoplasmic surface, which has 
four loops, the fourth loop is bound to a helix only by its amino terminus. The charge 
pair Glu134/Arg135, conserved in all the G-coupled receptors, is required for binding 
transducin to metarhodopsin II (Khorana, 1992). Meta II decays to form either, 
apoprotein opsin, and all-trans-retinal or converts to a meta III by-product. Meta III has 
absorbance maximum 465 nm, and meta II an absorbance maximum of 380 nm. Meta 
III  decays into free retinal and opsin, however interaction with Gt will enable it to form 
a meta II like species. Meta III can also serve as a storage for all trans-retinal, as it is 
toxic when free (Lomonosova, et al., 2012).  
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1.4 The Photo transduction cascade with emphasis on the importance of 
functional rhodopsin 
Rhodopsin in the outer segment absorbs a photon of light, that causes the 
isomerization of 11-cis-retinal to all trans retinal, leading to a change in conformation 
state and thus activating rhodopsin. The activated rhodopsin interacts with the G 
protein transducin thereby catalysing the exchange of guanosine diphosphate.GDP 
for guanosine triphosphate GTP (Sung & Chuang, 2010). Transducin is made up of α, 
β and γ subunits, and is present along the membrane of the outer segment. This 
activation of transducin leads to the dissociation of α subunit GTP from the transducin 
and rhodopsin complex. The αGTP subunit activates the enzyme cyclic guanosine 
monophosphate cGMP- phosphodiesterase (PDE), which catalyses the hydrolysis of 
cGMP to 5’GMP. PDE is a peripheral protein which is tightly bound to an inhibitory 
protein in the dark; the αGTP subunit competes with this. This leads to a decrease in 
the concentration of cGMP levels, causing the cGMP gated channel to close, causing 
increased levels of calcium and sodium in the plasma. In response the cell  
hyperpolarizes, leading to a membrane potential of -75 mV (Reminington, 2011). 
Every rhodopsin activates at least 500 molecules of transducin, which each activate a 
PDE leading to the hydrolysis of 4,200 molecules of cGMP (Cox & Nelson, 2013).  
To deactivate this membrane potential, the rhodopsin must be desensitised. 
Prolonged illumination of the rhodopsin protein leads to the exposure of Thr and Ser 
residues on the carboxyl-terminal domain, these residues are phosphorylated by 
rhodopsin kinase (Cox & Nelson, 2013). Rhodopsin kinase is not activated in the dark 
as the calcium binding protein, recoverin, binds to rhodopsin kinase when calcium 
levels in the cell are high. The re-coupling of the G trimeric protein occurs, the αGTP 
subunit has intrinsic GTPase activity, that can hydrolyse GTP back to GDP, causing 
the α subunit to dissociate from cGMP-PDE and re-associate with the trimeric protein 
transducin (Cox & Nelson, 2013). The rhodopsin protein binds with arrestin 1 which 
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prevents rhodopsin interacting with transducin. The lack of interaction with transducin 
causes a decrease in PDE activity, followed by the enzyme guanylyl cyclase being 
activated by GCAP and converting GTP to cGMP. GCAP is normally inhibited in the 
light by high calcium in the cell.  
The all-trans-retinal is converted to all-trans-retinol in the outer segment. All-trans-
retinal leaves the cell to the RPE to be converted back to 11-cis-retinal. The 11-cis- 
retinal is then transferred back to the photoreceptor to begin the cycle again (Sung & 
Chuang, 2010) 
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1.5 Introduction to retinitis pigmentosa its prevalence and Importance 
Retinitis pigmentosa (RP) is the name given to a group of progressive degenerative 
inherited disorders, that target the rod photoreceptors in the retina and causes their 
death or non-function, eventually leading to degeneration of cone photoreceptors. 
(Hartlong, et al., 2006). Caused by multiple different mutations, the pathogenesis of 
the disease varies dependent upon the mutation type and the age of onset. Retinitis, 
meaning retinal inflammation, is a misleading term as it does not occur in RP and 
‘pigmentosa’ referring to the melanin released by the RPE cells (Baumgartner, 1999). 
The name was originally coined by Dutch ophthalmologist F. C Donders in 1857 
(Donders, 1857).  
It is estimated that one in every four thousand of the world’s population suffer from RP.  
It is the most common cause of inherited visual loss (Zhang, 2016) (Hartlong, et al., 
2006) (Natarajan, 2011) (Verbakel, et al., 2018). It is the most common cause of 
inherited blindness with up to 25% of patients with RP become legally blind in both 
eyes (Natarajan, 2011) Research into the prevalence of non-syndromic RP in 
individual countries has shown no real difference based on location or ethnicity (Hamel, 
2014). In Kuwait this disease was the leading cause of visual disability of individuals 
under the age of 60. In Denmark, RP and optic neuropathy were the leading causes 
of blindness in people aged 20-64 years, making up 29% of cases (Hartlong, et al., 
2006). In Korea the overall prevalence is 1;9000 for all ages, increasing to a likelihood 
of 1:6000 for the over-40s. Korea also has higher mortality rates for those diagnosed 
with RP due to a high suicide rate among men of at working age (Na, et al., 2017). In 
Northern Ireland the rate is 1:3996 with a mean age of 50.4 years. (O'Neill, et al., 2007).  
It is probable that late examination, bad diagnosis, and abnormal presentation can 
lead to misinterpretation of prevalence (Zhang, 2016). The impact of RP is far reaching 
affecting the individual, and those around them, including their children, spouses, and 
elderly parents. As Korea highlights it there are not just negative physical 
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consequences but also negative effects for mental health. It is imperative that a cure 
for the disease is found as soon as possible.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
22 
 
1.6 Onset and progression of retinitis pigmentosa; Diagnosis and current 
treatment 
 Retinitis pigmentosa progression can be influenced by many different factors 
including mutation type, age, gender, and general health. Pin-pointing the ‘entry’ age 
of onset is difficult and ranges from childhood to adulthood (Hartlong, et al., 2006). 
This is because RP is fundamentally heterogeneous with one paper showing that even 
among siblings the progression differs (Colombo, et al., 2018) (Daiger, et al., 2013). 
The first symptom is night blindness, also known as nyctalopia (Ravichandran, et al., 
2019), which can have late or early age onset although typically found in teenagers. 
However, it has been known to show in late 20s and early 30s. The earlier the age of 
onset the more sever the RP (Hamel, 2006). In most cases the most severe type of 
RP is caused by recessive mutants which typically have earlier onset and are more 
likely to cause total blindness.  In its early stages RP may deliver peripheral visual field 
defects in dim light, however these are not apparent in the daytime. This symptom is 
not often caught when it first starts presenting as most people do not recognise it. This 
means the disease often progresses to cone damage before the sufferer seeks help 
(Hartlong, et al., 2006). It is believed that photoreceptor degeneration can start as early 
as 6, even in those who do not show symptoms until adulthood. The most effective 
means to diagnose RP this early is by the electroretinogram (EGR) (Hamel, 2006). 
The sufferer loses peripheral vision, eventually developing tunnel vision, the age of 
onset once again varies between groups, sometimes dependent on the RP mutation 
type (Daiger, et al., 2013). Timings between stages is individual to each sufferer and 
some never reach blindness, or tunnel vision, and maintain only a mild form of RP. 
Patients can lose up to 90% of their cone cells before visual acuities start diminishing 
(Hartlong, et al., 2006). Ultimately in the worse instances RP progresses to loss of 
central vision, and most patients fulfil the legal definition of blindness by age 40 
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(Hartlong, et al., 2006). However this is not always the consequence of RP and in most 
dominant retinitis pigmentosa the sufferer never presents this final symptom.  
There are three clinical findings which are indicate RP and thus are used as measures 
of diagnosis; bone spicule pigmentation, attenuation of retinal vessels, and optic nerve 
Pallor (O’Neal and Luther, 2019) (Ravichandran, et al., 2019). Bone spicule is caused 
by photoreceptor death which leads to a loss of pigment in the RPE, and a build-up of 
intraretinal melanin deposits (Athanasiou, et al., 2017), although bone spicule 
pigmentation is not apparent in all sufferers (Zhang, 2016). 
Figure 4 Labelled EGR images of a healthy eye, (right) and an eye with retinitis 
pigmentosa (left). This image highlights the different clinical findings used to 
diagnose RP ; attenuation of the blood vessels, pale optic disc, and bone spicule, 
all of which are not present [in]/[on] the healthy eye. This figure was adapted from 
(Schultz, 2013). 
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There is currently no cure for RP, but there are multiple treatments to slow progression. 
These include doses of vitamin A (no longer recommended as the relevant study was 
controversial (Natarajan, 2011)), light evasion, low vision aids, and more recently, 
more invasive methods such as Gene therapy, transplant research, and retinal 
prosthesis (Hamel, 2006). . 
Currently there are experimental gene therapy tests ongoing for RP, these include; 
MERTK delivery in RCS rats and mice, RNA interference in animal model, and CNGB1 
knock-out mouse model.  Due to low transduction efficiency of recombinant gene 
vectors it has lacked long term benefits.  Stem cell therapy using stem cells derived 
from bone marrow showed improvements within three months after treatment to 
quality of life for patients with RP but the effect was lost after twelve months (Zhang, 
2016). For gene therapy to be most beneficial the mutation of each sufferer must be 
known, this makes testing, and improvements of the treatment, difficult.  
While each of these therapies show varying degrees of success there is currently no 
universally accepted therapy.  
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1.5 Retinitis pigmentosa inheritance patterns with stress upon autosomal 
dominant RP  
Retinitis pigmentosa accounts for half of all inherited retinal disease cases (Daiger, et 
al., 2013). The first gene responsible for RP was [discovered]/[found] in 1990 (Zhang, 
2016) and the first mutation identified was P23H (Price, et al., 2011). Retinitis 
pigmentosa had been found to have nearly 3,100 mutations in more than 50 genes 
that cause non syndromic RP, more recently at least another 10 genes have been 
identified bringing the total to over 60 (Daiger, et al., 2019)   There are three main 
forms of inheritance: Autosomal dominant which encompass 30-40% of cases, 
Autosomal recessive with 50-60% of cases. and X-linked with 5-15% of cases. These 
figures assume that isolated cases are recessive (Natarajan, 2011) (Zhang, 2016) 
(Hartlong, et al., 2006). These three types of inheritance normally affect different 
genes and thus have different mutations and pathogenesis, however in some cases 
overlapping genes which can fall under more than one type of inheritance. The 
rhodopsin gene, Rho accounts for 25% of ADRP cases, and 8-10% of all RP cases 
(Comitato, et al., 2016) (Price, et al., 2011). 
RP is mainly non-syndromic however some 20-30% of RP cases show as part of a 
syndrome, and are categorised under 30 different syndromes (Hartlong, et al., 2006) 
(Zhang, 2016). The most common is Usher’s syndrome which is associated with a 
hearing impediment and is apparent in 20-40% of recessive cases: 12 genes are 
known to cause Usher’s syndrome (Hartlong, et al., 2006) (Daiger, et al., 2013). Other 
syndromes include Bardet-Biedl syndrome which has 17 genes linked [to]/[with] it, and 
is associated with obesity, renal disease, and cognitive impairment. These two 
syndromes alone account for 1,200 mutations clearly showing the heterogeneous of 
RP inheritance  (Daiger, et al., 2013). 
There are more than 150 documented missense/nonsense mutations on rhodopsin 
that cause autosomal dominant RP (Athanasiou, et al., 2017). 23 genes are known to 
26 
 
cause non-syndromic ADRP, 36 genes cause recessive, and 3 genes cause x linked 
RP, and around 20-25% of patients with ADRP have a mutation in rhodopsin (Hartlong, 
et al., 2006). The most common rhodopsin mutations are Pro23His and Pro347. The 
mutations of ADRP work in either a gain of function, or dominant-negative manner. 
The mutations found in rhodopsin are located all over the protein, those found in the 
cytoplasm tend to be more aggressive forms than those found in the extracellular 
space (Berson, et al., 2002). Interestingly the mutations located along the N-terminal 
have been linked to sector RP. Autosomal dominant is the mildest form with some 
sufferers not experiencing symptoms until age 50. 
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1.7 Different classifications of RP touching on their individual progression  
A classification of the different types of mutants on the basis of pathology was 
introduced originally by Mendes and further reflected upon in other papers (Mendes, 
et al., 2005). In the original classification seven classes were found (Classes I, II, III, 
IV, V, VI, and VII), in subsequent papers these have been further compartmentalised 
and an  class (VIII) has been added (Rakoczy, et al., 2011).  
Class I mutations fold normally but have poor/no transport to the outer segment, due 
in part to the changes in the C-terminal caused by the mutations (Mendes, et al., 2005).  
Class II mutants are retained in the ER due to partial/misfolded rhod-opsins. During 
further assessment this class was divided into three sub-classes: Class IIa, Class IIb 
and Class IIc, sharing the following characteristics; destabilisation of the protein 
according to foldX, interference of the retinal binding area, and polar/charged residues 
interference with integration into the membrane and rhodopsin stability (Rakoczy, et 
al., 2011). Other changes to Class II include removal of T17M from class II to class IV 
due to glycosylation effects (Rakoczy, et al., 2011). P23H/A was classified as a Class 
IIa mutant. Class III: mutants effect endocytosis (Mendes, et al., 2005). Class IV have 
altered post translational modifications and affect stability of rod-opsin. T4K which was 
originally in this class has been moved to Class IVa (Rakoczy, et al., 2011). Class V 
show an increase in transducin activation. Class VI activate opsin without a 
chromophore and in the dark. The final class according to Mendes was just 
‘unclassified’ showing no biochemical or cellular defect (Mendes, et al., 2005). Class 
VII is a new class of mutants which affect binding partner proteins, such as transducing 
or involve in dimerization of chromophore (Rakoczy, et al., 2011). 
  As previously stated, different mutants affect different genes, which in turn 
affect different proteins and thus different processes. One possible pathway for 
photoreceptor death is ER stress; accumulation of misfolded Class II mutants in the 
ER can lead to ER stress initiating UPR. In a normal process UPR can reduce the 
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number of misfolded proteins however if the stress is not elevated it can instead initiate 
apoptosis. Class II mutants can also be retro-translocated from the ER and undergo 
degradation by the ubiquitin-proteasome system (UPS), but if it is not degraded in this 
manner it can aggregate in the cytosol (Mendes, et al., 2005). Pharmacological 
chaperones is a possible therapy, especially of those class II mutants such as P23H. 
The hope is it will promote the trafficking and folding of these mutant rhodopsin, thus 
limiting the toxic effects of the mutants. AMPK activator metformin which alters cellular 
miliey and the rate of translation is another way to promote folding in mutated 
rhodopsin; however this leads to an unstable rhodopsin mutant (Athanasiou, et al., 
2017)   
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1.8 The current understanding of the pathologies of the chosen N-terminal 
      mutations  
 For the purposes of this experiment we are focusing only on the mutations located 
within the N-terminus of rhodopsin which are believed to cause Sector RP. As 
previously discussed, Sector RP only effects a segment of the retina and often leads 
to blindness in a specific location. These mutations are autosomal dominant, and while 
increasing the likelihood of presenting symptoms do not lead to severe symptoms such 
as full medical blindness. The mutations that we will be focusing on are; P23H, Q28H, 
P23A and T4K.  
The N-terminal is of great interest because it is highly conserved. It is believed that 
mutations here can destabilise the protein by decoupling interactions of the cap with 
extracellular loops (Opefi, et al., 2013). The current belief is that these mutations lead 
to improper folding and inability to leave the ER. The ADRP mutants in the N-terminal 
such as P23H are some of the most common; P23H accounts for the largest fraction 
of ADRP mutations in the United States. (Opefi, et al., 2013). Many experiments on 
the mutations within the N-terminal have looked at 11-cis mediated pharmacological 
rescue as a means to treat the disease, 11-cis binds to rod opsin and  is abundant 
throughout the cell, circulating the ER (Opefi, et al., 2013). It is thought that the 
pharmacological rescue of these mutated rhodopsins occurs naturally, allowing 
mutants to be transported to the OS, effectively going from a Class II mutant to a Class 
IV. 
There has been evidence that while this occurs, the mutant is truncated via a protease 
in the ER, possibly to stabilise the rhodopsin. One study found a 28-Kda band on the 
P23H/L which was also seen at lower levels in P23A, T4R and T17M, this band has 
also been located in transgenic frog and mouse models (Tam & Moritz, 2007). The 
band is caused by a N-terminal truncated product of opsin that, under further 
observation was found to be a 2:1 mixture of two polypeptides, which were consistent 
with cleavage after Tyr29 and Pro23 (Krebs, et al., 2010). It is not known how this 
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mutant will be affected after interaction with light, although presumably, given the lack 
of N-cap, the rhodopsin will be unable to reform properly within the cell. It follows  that 
these mutants would be sensitive to light, which is the case for T4K and T17M (Tam, 
et al., 2014), among other mutants that cause sector RP. For my thesis I have 
investigated the mutants T4K, P23H/A and Q28H, their location along the N-terminal 
produce different effects phenotypically, however they are all rescued in much the 
same manner.  
T4K along with T17M sit on the N terminal close to glycosylation sites N2 and N15 
(Zhang, 2016). The glycosylation of rhodopsin is believed to be critical to its ability to 
function. The glycosylation at N2 is not needed for the function of rhodopsin it is 
needed in N15 which is why the T17M is more toxic than T4K. There is also evidence 
that the toxicity of these mutants relies heavily on light, as they are less toxic in inactive 
and dark states. For conformational maturation and interaction with molecular 
chaperones rhodopsin requires N linked glycosylation in the ER (Tam, et al., 2014).  
 
P23H mutation is much more severe than the P23A mutation, due to P23H having a 
more severely misfolded phenotype. The mutants T4R, T17M, and Pro23, all display 
unusual photobleaching behaviour. In the photochemical reaction pathway these show 
more metarhodopsin I like, and less metarhodopsin II like, characteristics immediately 
after illumination, implying that some molecules are converted into ground state, or 
into a isorhodopsin, during photobleaching. These intermediates are more light 
sensitive, and accumulation of these light sensitive decay products may be cytotoxic. 
Some of these variants may produce Intermediates which are unable to bind arrestin 
(Krebs, et al., 2010).  
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Figure 5 A schematic diagram of the secondary structure of rhodopsin. This 
image shows the location of the mutations on the N terminus (highlighted in yellow) 
that will be used during the experiments; T4K, P23H/A and Q28H (highlighted in 
red). This diagram also indicates the binding location of 1D4 Sepharose which is 
the TETSQVAPA sequence (highlighted in green) located on the C-terminus, and 
the location of binding for Con A – Sepharose which is the glycan moieties 
extending from N2 and N15 located on the N terminus of rhodopsin. The location 
of 11-cis-retinal binding has also been indicated at Lys 296 (highlighted in light 
blue). This figure was adapted from (Cha, et al., 2000). 
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1.9 Aims and hypothesis of thesis  
 
The aim of this project was to express and isolate the cleaved rhodopsin and 
characterise it using biochemistry and spectroscopy, to see how it differs form the non-
cleaved form. From this we hoped to increase understanding of the pathology of 
retinitis pigmentosa, this knowledge would help us to understand how the truncated 
rhodopsin causes retinitis pigmentosa, understanding its interactions with light and its 
ability to form intermediates such as metarhodopsin II.  
We hypothesised that using two forms of immunoaffinity chromatography we could 
isolate the two mutant species. The first separation used 1D4-sepharose which binds 
at the C terminus to the TETSQVAPA sequence. The cleaved and full rhodopsin 
mutant species have functional a C terminus, thus we can use 1D4- sepharose as a 
way to purify the sample. The second separation uses Con A-Sepharose which binds 
to the glycan moieties extended from the glycosylation sites N2 and N15 (De Grip, W. 
J.,1982). Previous work has shown that the N terminus of the cleaved rhodopsin 
species is removed, this means it would be unable to bind to the Con A -Sepharose, 
allowing it to flow through. The full mutant rhodopsin species will bind to the Con-A 
sepharose thus isolating the two forms of rhodopsin.  
If we can achieve this, we will then run photobleaching analysis and meta II rhodopsin 
decay analysis to better understand the characteristics of the ADRP rhodopsin mutant 
species. Once this species is isolated, we can use it to locate the kinase/kinases 
responsible for the truncation of rhodopsin. 
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Chapter 2) Methods  
2.1 DNA Preparation 
2.1.1 Formation of agar and broth  
2xYT Agar:  
• 16g/L of tryptone;  
• 10g/L of yeast extract; 
• 10g/L Na Cl; 
• 16g/L agar. 
Media was made up in RO water, aliquoted in 250ml sizes into 500ml Duran bottles, 
and autoclaved.  
2xYT broth: 
• 16g/L tryptone; 
• 10g/L yeast extract; 
• 10g/l NA Cl.  
Media was made up in RO water, aliquoted into 3ml universal tubes, and autoclaved. 
All media was stored at room temperature. 
2.1.2 Formation of agar plates 
2xYT agar was warmed in a microwave until molten. The agar was left to cool to 
between 55°C and 40°C, and 100µg/ml filter sterilised ampicillin was added. The 
counter was sterilized with ethanol, and a bunsen burner lit in accordance with aseptic 
protocol. Agar was poured into 10cm petri dishes and left to dry in close proximity to 
the bunsen burner. The agar plates, once dry, were stored in the refrigerator for further 
use.  
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2.1.3 Generation of competent Escherichia coli cells  
E. coli Cells previously prepared (Opefi, 2011) were used, Opefi’s protocol is briefly 
outlined.  
Transformation Buffer [(TB) (500ml)]:  
  HEPES (1.18g); 
  Cacl2  (1.1g); 
  KCl    (9.3g). 
pH adjusted to 6.7 with 10M KOH  
  Mncl2 (5.4g)  
  Final volume adjusted to 500ml. 
  TB was filter sterilized and stored at 4°C 
  
Using a wire loop and aseptic conditions XL-1 Escherichia coli was struck out to single 
colonies on a non-ampicillin plate. A starter culture, made of a single colony 
suspended in 3ml 2xTY media without antibiotic selection, was grown over night (16hr) 
at 37°C on a shaker at 250rpm (New Brunswick Scientific Innova-4000). 100µl starter 
culture was inoculated into 250ml 2xYT media in a 2-L flask, which was incubated at 
22°C with shaking at 200 rpm until the optical density of culture reached an 
absorbance of 0.6 at 600nm. Growth at 22°C was preformed was a refrigerated 
incubator shaker (New Brunswick Scientific Innova-4330), and 0.6 absorbance was 
attained by XL-1 blue cells within (26-30) h.   
The cells were chilled on ice for 10 mins after growth, as well as all solutions. Cells 
were harvested by centrifugation (Jouan CR-312) at 400rpm at 4°C for 10 min. The 
pellet was resuspended carefully in 80ml of ice-cold buffer TB, re-centrifuged at 400 
rpm at 4°C for 10 min. Supernatant was removed again, and the pellet suspended in 
20ml ice-cold buffer TB. 1.5ml of high grade DMSO (sigma D-2650) was slowly added 
to the cells while swirling gently to ensure proper mixing. The cell suspension was 
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incubated on ice for 20min and aliquoted in 100µl or 200µl volumes into ice-chilled 
sterile 1.5ml tubes. The cells were snap frozen in liquid nitrogen and immediately 
stored at -80° C. 
2.1.4 Transformation of E.coli cells  
3µl of the DNA sample was added to 30µl of competent E.coli cells, left on ice for half 
an hour, and heat shocked for 45 seconds at 42⁰C, before being immediately put on 
ice for 5 minutes. 500ul 2xty broth was added and put on a shaker at 250rpm for 30 
mins at 37⁰C-, (5mins on super coiled DNA). 50ul was pipetted onto each 2XTY plate 
containing ampicillin (100µg/ml) and spread; all completed under aseptic technique. 
The plates were then incubated at 37°c for 16 hours to allow colonies to form.  
2.1.5 Construction of ADRP mutant genes  
The plasmids used for this experiment were previously created for Chikwado Alo 
Opefim. They were constructed using QuickChange site directed mutagenesis.  
2.1.6 DNA Sequencing  
Sequence analysis was conducted out of house by SourceBiosciences. They were 
sequenced backwards and forwards in the case of the TETO plasmids, and the other 
mutants were tested normally. 
2.1.7 Mini-scale DNA preparation 
The mutant or WT plasmid DNA was grown on ampicillin plates; one colony was 
selected from each plate and inoculated in 3ml of 2xty broth with ampicillin, again at 
100 mg/ml, and left on a shaker for 16 hours (or over-night) at 37°C. 1 ml of the culture 
was inoculated into a microcentrifuge tube and spun at maximum speed for 3 minutes 
at RT. The suspension was removed, and the pellet prepared using the Thermo Fisher 
Scientific Mini-prep kit (Fisher,2019). The elution buffer was replaced with miliQ water 
at 65°C; 500 µl was used. The concentration and quality of the DNA was measured 
using a nanodrop spectrometer. The sample was kept at-20°C until used.  
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2.1.8 Midi –scale DNA preparation  
Plasmid DNA was grown on ampicillin plates and the culture left to grow over-night. A 
single colony was selected and inoculated in 2XTY broth with ampicillin at 100mg/ ml. 
The suspension was put on a shaker for 6-7 hours at 250RPM at 37°C. An aliquot of 
this was inoculated into a 1 L conical flask of 2xty broth (100 ml), again with ampicillin 
at 100 mg/ml. The broth was left on the shaker over- night at 37°C at 200RPM. The 
broth was removed and divided into two 50ml centrifuge tubes centrifuged at 4,500 
rpm for 5 mins at RT. The pellet was kept at -20°C until use. The pellet was prepared 
using the Thermo Fisher Midi Prep kit (Fisher, 2019). The DNA was eluted, and the 
concentration tested as in 2.1.7.   
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2.2 Tissue cell culture  
The cells used in this investigation are human embryonic kidney 293s cells which were 
previously stored in cryogenic tubes at -80°C. The cells were grown under sterile 
conditions in a tissue culture laboratory. The cabinet used was a class II type A2 
biological safety tissue culture hood (sanyo NU-427-400) equipped with vertical 
laminar flow and UV light for decontamination. PPE was worn where appropriate. 
2.2.1 Tissue cell culture media  
Full DMEM, and DMEM F12, were supplemented with; 1% penicillin streptomycin, 
10% foetal bovine serum, and 1% stable glutamine. 
The media and its supplements were warmed to 37°C and mixed together in a tissue 
culture cabinet under sterile conditions. All media was stored at -20°C 
2.2.2 Growing stocks from frozen  
HEK 293s cells, and supplemented DMEMF12, were warmed to 37°C in a water bath 
and washed with 70% ethanol before being moved to a tissue culture lab where they 
were disinfected using 2% chem gene in accordance with aseptic technique. The cells 
were added to a 15 ml centrifuge tube, and 10 ml supplemented DMEMF12 was added 
drop wise. The cells were centrifuged at 1,000 RPM for 3 minutes at RT. The 
supernatant was removed, and 10 ml of supplemented DMEMF12 was used to 
resuspend the cell pellet. The suspension was added to a 10 cm TC plate which was 
incubated at 37°C with 5% C02.  
2.2.3 Sub culture and splitting cells  
         10 cm plate 
        When cells reached 90% confluence they were divided, every two days thereafter 
the cells were further divided at a 1:4/ 1:5 ratio. PBS, supplemented DMEM F12 and 
trypsin were prewarmed to 37°C, in a warming cabinet. The plate was removed from 
the incubator to a pre-disinfected TC hood. The old media was removed using an 
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aspirator containing chem gene at 5%. The cells were washed with 10 ml PBS and 
then aspirated off; 1 ml of trypsin was added, and the plate placed in an incubator for 
2mins. 8ml media was added to two new plates, and 7.5 ml added to two other new 
plates for a 1:5 and 1:4 split. The original plate was removed and the trypsin inactivated 
by 9ml of media. The media was pipetted up and down the plate to remove all cells 
and assure a 1 cell suspension. 2 ml of this media was added to the 8 ml plates, and 
2.5 ml added to the 7.5 ml plates. The plates were then moved from side to side to 
achieve full coverage of the plate and avoid grouping. The plates were to an incubator 
at 37°C with 5% C02.  
        15 cm plate 
        As for the 10 cm plate, except with 15 ml PBS and 2 ml of trypsin. A previously 
autoclaved 250 ml duran bottle was filled with 65 ml of supplemented DMEMF12 
media. The plate was removed from the incubator and 8 ml of media added, then 
pipetted to get a single cell suspension. The media was added to the 250 ml duran 
bottle, then swirled. 18 ml of this media was distributed via a pipette to the four plates. 
The method then followed that for the 10 cm plate. 
2.2.4 Freeze down  
When the HEK 293s cells achieved 90% confluence the media was aspirated, the 
plate was washed with pre-heated PBS and either 1 or 2 ml of pre-heated trypsin 
added, the plate was incubated at 37°c and 5%C02 for 2 minutes. The trypsin was 
inhibited by the addition of 8 or 9 ml of pre-heated supplemented DMEMF12, the 
suspension pipetted up and down ten times to ensure single cell suspension. The 
suspension was transferred to a 15 cm tube, and spun at 1,000 rpm for 3 minutes at 
RT. The supernatant was removed, and the pellet re-suspended in 10 cm freezing 
serum (90% supplemented DMEM :10% DMSO). The suspension was aliquoted into 
freezing vials for storage at -80°c. 
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2.2.5 Preparation of 9 cis retinal  
Stock Solutions   
Stock solutions of 10 mM were made using 25 mg 9 cis-retinal (Sigma R5754:514-85-
2). The 9 cis was dissolved in ethanol, added to a 15 ml tube and left to rock until 
dissolved. The stock solution was aliquoted into freezing vials and sealed with Argon, 
the vials were wrapped with foil before being stored at -80°c. 
Working solutions   
An aliquot of stock solution was removed and aliquoted further for final concentration 
of 20 µM. The retinal solution underwent evaporation of ethanol by argon, and 
subsequent re-suspension in cell culture grade DMSO.  
 
2.2.6 Transient transfection of mutant rhodopsin  
The HEK 293s cells were grown in supplemented DMEMF12 until confluent and then 
split for 35-40% confluence in complete DMEM. Transfection was completed using the 
CaCl2 method as previously denoted, briefly per 10 cm plate; 27 µg Rho-pMT4 DNA, 
and 3 µg pRSV-Tag DNA, were made up to 450µl milliQ water in a 15 cm tube. 2.5 M 
CaCl2 was added drop wise to the solution under constant vortexing followed by 2X 
BES buffer which was added drop wise under time constraints. This 1 ml solution was 
added gently drop wise to the plate of HEK 293s cells while being briefly swirled. The 
cells were incubated overnight at 37°c and 1% C02. The old media was removed and 
the cells washed using PBS, new media was added and the cells incubated at 37°C 
and 5% C02 for 48 hours. The cells were harvested and pelleted down, the supernatant 
removed, and the pellet re- suspended in 1.5 ml PBS. The 2 µl 9-cis-retinal from stock 
was added to cell suspension and, in dark conditions incubated at -20°C for 3 hours 
in a nutator. Thereafter the cells were wrapped in foil, snap frozen, and stored at -80°C. 
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2.2.7  Transfection with retinal rescue     
The transfection solutions were added as described above and left for 24 hours. The 
transfection solutions were removed, the cells washed, and new media added. The 
cells were subsequently rested in an incubator at 37°c and 5% C02 for approximately  
six hours. The 20 µM 9-cis-retinal previously prepared in methods section 2.2.5and 
under dark light and sterile conditions was added drop wise to the plates. The plates 
were gently swirled before being wrapped in foil and placed back in the incubator at 
37°c and 5% C02. The procedure then follows the methods described in section 2.2.6. 
2.2.8 Stable cell line transfection of mutant rhodopsin   
Plasmids, suitable for use in creating a stable cell line, were grown from frozen 
following procedures described in section 2.1 and more specifically: 2.1.2 to 2.1.4 and 
2.1.6. The plasmids were created as previously described in (Reeves, et al., 2002) but 
briefly the plasmid contains two TETO sequences (tetracycline-inducible expression 
system) attached to a CMV promoter, the acetylcholine esterase Ach(nc) gene and 
the rhodopsin gene, creating the pACMV-tetO-Rho plasmid. This plasmid was mutated 
so that it produced either P23H or P23A rhodopsin. 
The HEK293S cells used in the experiment were previously transfected with the 
pCDNA6-TR (Invitrogen) plasmid containing genes encoding the selectable marker 
blasticidin and the tet operon repressor protein (TetR). The cells were brought up from 
frozen (as previously described in methods section 2.2.2) and were selected based on 
basticidin (5µg/ml) resistance. Those cells showing resistance were expanded under 
blasticidin selection and transfected with plasmid pACMV-tetO-Rho using the calcium 
method described in method 2.2.6. After 48 hours geneticin (2 mg/ml) selection was 
initiated, and colonies appearing after 14 days were isolated and expanded on a 24 
well plate. The cell lines were divided1:3 down the lanes. The first well was frozen and 
stored at -80°C, the second well supplemented with growth medium, and the 3rd dish 
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induced using tetracycline (2 µg/ml) and sodium butyrate (5mM). The wells were left 
for a further 24 hours, harvested, and frozen at -80°C. 
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2.3 Protein purification 
      All purification and separation procedures were carried out in the dark or  
     under safelight filter and at 4°C 
     2.3.1 Purification of mutant rhodopsin via rho-1D4-Sepharose beads 
 Purifications started with original samples of WT between 80-100 µg, and mutant 
types between 40-60 µg, as calculated from the UV Spectra (2.4.2) of the harvested 
transiently transfected rescued cells (2.2.6).  
Buffer A – solubilisation buffer  
 0.1% DDM; 
 0.5 mM PMSF; 
 made up in 1x PBS.  
Buffer B – Wash Buffer  
 Buffer A – without PMSF 
Buffer C – Elution Buffer 
 Buffer B + 100 µM Rho-1D4 peptide 
The sample was brought to 2 ml in buffer A and, in the dark, rotated for an hour at 4°C 
before centrifugation at 4,500RPM at 4°C for 30 minutes. 50% of 1D4 slurry 
(Amersham Pharmacia previously prepared in 50% slurry in PBS) was added to the 
sample and left, in the dark, to rotate at 4°C for a further 2 hours. The suspension was 
loaded into a disposable polypropylene column (Thermo Scientific 29920) equipped 
with a porous disc (frit) and capped. The column was suspended over a 100 ml 
measuring cylinder. 10 ml of buffer B was added to the column, then another. The 
column was capped and incubated overnight at 4°C overnight. The wash buffer was 
allowed to flow through the column before100 µl of buffer C was added and also 
allowed to flow through. The column is capped and a further 500µl of buffer C was 
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added to the column, the column was incubated for an hour at 4°C. The column was 
then uncapped and the flow through collected in a second centrifuge tube. The process 
of adding 500 µl of buffer C and incubation for an hour at 4°C was repeated a further 
3 times. The UV spectra was then taken. 
2.3.2 Protein Purification using CON A- Sepharose beads  
Buffer A – Solubilisation Buff  
0.01M CaCl2; 
0.01M MnCl2; 
0.05M NaCl2;  
0.01% DDM; 
made up in 1% PBS  
Buffer B – Wash Buffer  
Buffer A made up in 7.6 pH Tris HCl 
Buffer C – Elution buffer  
Buffer B + 0.3 M of Methyl α-D-Mannopyranoside 
The centrifuge spin columns were prepared, and 0.03 ml of Con A beads in slurry were 
added to it. The column was washed 10 x with 250 ul of buffer B. A small aliquot of the 
Sample was removed for Western blot analysis, the remainder of the sample was 
made up to 1.5 ml in buffer A. The Sample was rotated for an hour at 4°C before 
centrifugation for 30 mins at 14,000 RPM at 4°C. The pre-prepared spin column was 
transferred to a fresh 1.5 ml centrifuge tube, and the Sample added to the spin column. 
The centrifuge tube containing the spin column was rotated for two and one half hours 
at 4°C using a mini centrifuge, and a UV spectra taken to confirm full binding. The spin 
column was transferred to a fresh centrifuge tube and 500 µl buffer B was added, the 
column spun down again and another UV spectra taken. Thereafter the column was 
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transferred to a fresh centrifuge tube,  500µl buffer C was added to the column, which 
was rotated for a further hour at 4°C, the column was again spun down and again a 
UV spectra taken. This was repeated for a number of elution fractions until all 
rhodopsin had been collected. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
45 
 
2.4 Analysis of samples  
2.4.1 Western blots and SDS page analysis 
See appendix section 1.1 for buffers. 
Glass slides were washed in succession with 1% SDS, 70% ethanol, and RO water. 
The gel rig was assembled according to the manufacturers’ instructions. The resolving 
gel solution was made up, loaded into the gel rig, and overlayed with 0.5 ml of water-
saturated iso-butanol.  
The running gel (appendix section 1.1 Table 1 referred), was left to polymerise and 
washed thoroughly with RO water, and dried using blotting paper. The stacking gel ( 
appendix 1.1 Table 2 referred), was loaded and the 10 well comb was then added 
immediately, and the gel left to polymerise.  
The gel cassettes were placed into the clamping frame as per the manufactures’ 
instructions. The electrode assembly was placed in the buffer tank, and 1x tank buffer 
was added to the assembly just under the gel plate. The comb was removed and the 
gels syringed with 1X tank buffer, this was left so leaking could be monitored. The 
samples were prepared; separately 64 µl of 4x loading buffer was added to 16 µl of 
mercapethanol, and 4 µl of this solution was added to 12 µl of the samples. The ladder 
was also prepared using 1x loading buffer and a prestained protein page ruler, product 
number 26616. The samples were added to the wells, with a detailed note of the order 
being was made. The Hoefer ps300-B power pack was attached and set at 200V 
initially for an hour and additional time added as necessary to ensure the dye had 
travelled down the gels.  Transfer buffer was added to a clean tray, and four blotting 
papers of the correct size were submerged together with a membrane, the sponges, 
and the clamp. The gels were then removed and one placed in coumassie stain and 
left on a rotator for an hour, another was submerged into the transfer buffer. The clamp 
was assembled according to manufacturers’ instructions in the order: one sponge, two 
46 
 
blotting papers, the membrane, the gel, two further blotting papers, and another 
sponge; any air bubbles were rolled out gently before the clamp was tightened. The 
clamp was then added to the assembly, in accordance with the manufacturers 
instruction, with the addition of a magnetic stirrer, an ice pack and the assembly being 
placed in an ice bucket to keep temperatures down. The power back was set to 100v 
for an hour, thereafter the membrane was removed to the blocking buffer and left 
overnight on a nutator at 4°C. The coumassie stain gel was removed from the rotator 
and kept overnight at 4°C, before a photograph was taken of the gel. The western blot 
membrane was washed with 1x PBS, primary antibody was added and left on a nutator 
for 5 hours, washed using the wash buffer 5x for 5 minutes, secondary antibody is 
added for one hour and washed a further 5x with the wash buffer, finally the ECL was 
added and incubated at RT for 1 min. The membrane is then wrapped gently in cling 
film and attached to the detection chamber of a radiographic cassette. The remainder 
is performed under dark conditions: a photographic film is exposed to the membrane 
for 10-60 seconds, the film is placed briefly in a developer, washed in RO water, and 
then submerged in a fixer solution for 10 minutes before being washed again with RO 
water. The film is then left to dry.   
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2.4.2 UV spectroscopy  
Appendix section 1.2 for buffers referred. 
UV visible spectroscopy was taken using the Perkin-Elmer λ25 UV/vis 
spectrophotometer equipped with water-jacketed cell holder. The room and water 
jacketed cell holder were at 19 °C, with the samples being kept in dark conditions at 
4°C. The data interval was set at 2 nm bandwidth with a response time of 1 sec and a 
scan speed of 480 nm/min, and spectral scans taken between 650 nm and 250 nm 
wavelengths. The samples were analysed using UV spectroscopy include; samples of 
transiently transfected harvested cells solubilised in DDM (2.2.4), multiple stages of 
1D4-sepharose purification in section 2.3.1, and multiple stages of CON-A – 
sepharose separation in section 2.3.2. Blanks were made up of the buffer in which the 
sample had been solubilised. The inside of the curvet was cleaned using 1% DDM, 
RO water and 100% ethanol in that order, and the outside cleaned using non scratch 
wipes. 
An aliquot of the samples of harvested cells in section 2.2.4 was made up to 500 µl in 
buffer A, mixed end over end in the dark for 1 hour at 4°C, and centrifuged for 30 mins 
at maximum speed at 4°C. The blanks were made up using buffer A and the 
spectroscopy machine was prepared. Each sample was then measured under dark 
conditions before photobleaching for 60 seconds using a fibre optic guide directly to 
the curvet, and the UV spectra was re-checked. The samples were saved for western 
blot analysis. The two UV/Vis spectra were then compared, the bleached sample was 
zeroed to the dark spectra, and the zeroed bleached spectra was subtracted from the 
dark spectra to create the difference spectra, which was used to calculate the amount 
of rhodopsin present in the sample.  
The blanks for the stages of the purification and separation protocol can be found in 
section 2.3 
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2.4.3 Dot blots  
Appendix section 1.3 for buffers referred. 
Transiently rescued T4K sample, previously analysed by western blot, was used as a 
positive control, and untransfected harvested cells, previously analysed by western 
blot, were used as a negative control. The stable cell line pellets were re-suspended/ 
solubilised in buffer A. The samples were mixed end over end at 4°C for an hour and 
centrifuged at maximum speed for 30mins at 4°C. The dot blot apparatus, 96-well Bio-
Dot®, was assembled according to manufacturers’ instructions, appendix section 
referred. Samples were prepared in the 96 well plate. 75 µl of buffer B was added to 
each well using a multichannel pipette. 25 µl of each sample was added to the first 
row, using the multichannel pipette. 25 ul of the first row (A) was moved to second row 
(B), and so on to dilute the sample. Nitrocellulose paper was soaked in buffer C before 
assembly. Samples were loaded into the apparatus and run through, 4X 150 µl of 
buffer C was added and left to run. Once all samples had run dry, Nitrocellulose 
paper/membrane paper was left overnight in buffer D. Buffer D was removed, the 
membrane washed twice with 1X PBS. The protocol then followed as seen in western 
blot section 2.4.2.  
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Chapter 3) Results of initial plasmid and protein testing. 
3.1 Verification of plasmids  
The plasmids used during this project were taken from previously made glycerol 
stocks. The plasmids were sent to Source Bioscience for sequencing to confirm the 
presence of the mutations and to check for deterioration. Figure 6 shows the primary 
sequence of the four different rhodopsin mutations. The full plasmid sequence was 
analysed and showed little to no deterioration or further mutations to the sequence. 
With this validation, we moved on to increasing the amount of DNA present to allow 
for the transfection protocols.  
CCG -> 
CAC  
A 
CCG -> 
GCC 
B 
AGT 
->ATT  
C 
ACC 
->AAG  
D 
Figure 6 The sequenced plasmid DNA of mutated rhodopsin. This diagram 
was created using snap gene. The sequences are the forward strand in the 5’→ 3’ 
direction, using primer F1 (SEQF1) A) P23H, B) P23A, C) Q28H D) T4K. The 
mutation can be seen highlighted in red with the original and new sequence in the 
black box below. These mutations are located on the N terminus of the rhodopsin 
protein.  
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3.2 The production and separation of the rhodopsin protein with subsequent 
calculation of yield. 
DNA was amplified for the use of transient transfection to obtain rhodopsin samples. 
The calcium-phosphate method of transfection was chosen due to its reasonable 
efficiency and low cost. The cells were treated with -cis-retinal to rescue the mutated 
rhodopsin, as this has been proven to help the rhodopsin to fold sufficiently. In vivo 
the retinal is 11-cis but 9-cis-retinal was used as an alternative since the expense of 
using 11-cis-retinal is high and they have similar structure and interactions with 
rhodopsin (Sekharan, 2011). This causes no real difference to the results; however, 
the UV VIS Spectra will be slightly left shifted with full rhodopsin showing at 490nm, 
not 500nm as is shown for 11-cis-retinal. 
Figure 7. shows the visible UV spectra of transiently transfected WT-rhodopsin. Figure 
7.A is the original output showing both the dark spectra and bleached spectra together, 
this image was then magnified to produce figure 7. B with the intention of seeing a 
clearer difference between dark and bleached spectra at 490nm. The difference 
spectra can be seen in figure C.  
Figure 7. A has a peak at 280 nm which is roughly 0.7, however we cannot see a clear 
peak between 490-500 nm which indicates low yield of rhodopsin. Figure 7.B shows a 
significant difference between the dark and bleached spectra indicating that some 
rhodopsin has been produced from the transfection, however a cleaner peak would be 
preferable. Figure (7.C) shows a clear peak between 490nm and 500nm, indicating a 
good yield of rhodopsin. 
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The concentration of the rhodopsin was calculated for figure 7.C as follows;  
 Using the absorbance of the peak at 490nm from the difference spectra and the beer 
lambert law, assuming total volume: 1,500 µl, molecular Wight of rhodopsin: 40,000, 
Extinction co-efficient of rhodopsin:40,600 and path length:1. 
The sample used for figure (3.2.1) was a dilution: 150µl into a 500µl – a 10X dilution. 
The highest difference was 489nm having an absorbance of 0.005151 
0.005151/ 40600 x 1 = 1.268X10-7 
1.268X10-7 x 40,000 x 1,000 = 5.0748 µg/ml 
(5.0748/2) x 10 = 25µg in 500µl 
In the total sample of 1,150µl we would have 76.12 µg 
This is a low yield, the expected would be to have ~60µg within a 500µl sample.  
The 280nm peak visible in figure 7.A is caused by aromatic side chains, such as 
tryptophan and histidine, so is a good indication of protein presence. The protein 
measured in this peak can also be from contaminants and so can be used to monitor 
cell count at transfection level. In this instance from figure 7.A we see a peak of 0.7 
given this sample is at a dilution of 10x, we can assume this is a very high cell count. 
The number of cells at the time of transfection is important and a high density of cells 
can lower the protein yield. This peak could indicate that a lower number of cells would 
be needed to increase efficacy. The transfection protocol was run multiple times and 
adjustments such as cell density were made throughout the project to obtain the 
highest possible efficiency and thus yield of rhodopsin.  
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Figure 7 Wild-type control absorbance spectra. UV spectroscopy of harvested 
Hek293s cells which had been previously transfected with plasmids containing wt-
rho. The cells were transfected using the calcium method, pre-prepared 9-cis-
retinal was added to the rescued cells during the transfection protocol 48 hours 
before harvest, additional retinal had been added to all samples prior to testing as 
stated in methods. The samples were run before and after bleaching for 1 minute. 
For (A) and (B) Dark samples are black, bleached samples are red, the results had 
been zeroed prior to creation of the graphs. (A) The UV spectra output of Wt-rho, 
between 650-250nm, (B) zoomed in clearer graph of (A) showing wavelengths 550-
450nm, (C)The difference spectra, calculated by taking the bleached spectra away 
from the dark spectra. 
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Figure 8 is the difference spectra of the harvested rhodopsin mutants obtained from 
transient transfection. Figure 8 1.A-D is to magnify the peaks at 490nm and Figure 8 
2.A-D is to show the best comparison of the peaks at 490nm. We can see that P23A, 
figure 8. B had the highest concentration, 151 µg in 1.2ml. The second highest 
concentration was shown by Q28H at 71.3 µg followed by P23H at 20.7 µg and finally 
T4K with 16 µg in 1.2ml aliquots.  
This agrees with the paper (Opefi, et al., 2013) which found P23A to be the most 
receptive to retinal rescue and managed to get the mutant to express at WT levels. 
Unfortunately, we can’t definitively state that we managed to obtain WT levels of P23A 
due to inconsistency of the rhodopsin concentrations obtained from the transfections. 
The (Opefi, et al., 2013) paper also managed to express T4K at the same levels as 
WT we did not find this to be the case, this could be due to poor transfection or low 
quality DNA which as previously mentioned have an effect on the concentration of 
rhodopsin harvested.  
The 280nm/490nm ratio also known as the purity ratio as previously mentioned can 
be used to assess the efficiency of transfection, but it can also be used to monitor the 
degree of misfolding. The ADRP mutations chosen misfold within the ER leading to 
little production of rhodopsin, the 9-cis-retinal rescue aids in the folding of the protein 
leading to a lowered degree of misfolding and an increase of rhodopsin production. 
The increase of rhodopsin concentration and the increase of purity ratios are signs 
that the transfection and thus the retinal rescue worked well. The retinal rescue 
working means that the degree of misfolding has been lowered for the protein. We can 
compare these results of the mutants to each other to determine which of the mutants 
have the highest degree of misfolding. It is important to look at all results before 
determining this as many variables can effect the results obtained from the 
transfection. 
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 From figure 8 using the dark spectra of these samples we found ratios of 0.07 for 
Q28H, 0.05 for P23A, 0.05 for T4K and 0.004 for P23H. The high purity ratio for Q28H 
would indicate that this has the highest efficiency and thus the lowest degree of 
misfolding. From other papers we know that this has not been found to be the case, 
thus we must look at the wider picture. The absorbance at 280nm for each of the 
mutants were as follows: 1.14 Q28H, 1.505 P23A, 1.18 T4K and finally 0.68 P23H.  
Taking these into consideration we can see that P23A and T4K had the same ratio, 
which would indicate the same efficiency of transfection despite having large 
differences in concentration. Looking at the 280nm absorbance for P23A and T4k 
which was 1.505 and 1.18 respectively we can see a large difference, the peak at 
280nm is caused by aromatic side chains and so show the presence of protein, this 
can include contaminates. The difference in size of this peak can mean that there were 
not enough cells present at the time of transfection of T4K and thus the yield of 
rhodopsin is lower. This difference can also be slightly attributed to the increase of 
rhodopsin within the P23A sample. There is however clearly a discrepancy in the 
transfection of T4K, the cell density will have to be improved, in-order to increase the 
yield of rhodopsin and thus be in agreement with the (Opefi, et al., 2013) paper. P23H 
had the lowest absorbance and purity ratio and a low concentration of rhodopsin. 
There is clearly a fault with the transfection of this mutant, the cell density at 
transfection was obviously far too low and needs to be increased. Q28H produces the 
biggest outlier having been shown to only reach levels of ~50% of WT-rhodopsin 
(Opefi, et al., 2013), yet showing higher concentrations of rhodopsin than that of T4K 
it is most likely that the transfection for this mutant went far better than that of the 
others and thus gives the impression of a lower level of misfolding. If the objective had 
been to ascertain the level of misfolding further experiments of biochemical 
characterisation would have shown better the degree of misfolding despite the 
apparent high concentrations noted here.  
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Figure 8.D does not follow the standard shape, the rhodopsin peak at 490nm is low 
and broad and the graph does not dip at 390nm as is seen in figure 8.A-C.  This could 
indicate low yield, an excess of contaminants due to high cell count, or problems with 
the UV Vis Spectroscopy machine, which had a habit of overheating.  
The sample aliquot also had a high dilution of 12x which may have influenced the 
ability of the old machine to detect the low amounts of rhodopsin present. This may 
have affected the concentration calculated for T4K.  
It is important to note the difficulties that occurred while trying to increase the yield of 
transfection including cell count, buffer failure, and low-quality DNA.  
Transfections were tested to find yield and roughly determine the cell count. The 
values at 280nm together with the protein concentration calculated from the peak at 
490nm, are good indicators for cell count. It is possible to tell how well the cells were 
transfected, as a high peak at 280nm and a low protein concentration (peak at 490nm) 
can indicate that there were too many cells at the point of transfection. Low yield can 
also indicate that there were problems with the transfection itself such as; poor quality 
DNA or poor buffers. For the protocol used however it is most commonly the cell count 
that leads to poor 280nm and 490nm ratio, with a much lower 280nm indicating not 
enough cells. The expected value for 280nm in the case of 10cm plate in this instance 
is about 0.6 with the larger plates 15cm not bigger than 1/1.2. From this information 
we were able to work out the efficiency of the transfection and possible changes that 
needed to be made. The problems started when we began scaling up to using larger 
plates. In the end the cell count was determined to be the reason behind the low yields, 
having either too many or too few. We had to rule out however the likelihood of another 
factor, so new midi prep kits were used to increase the yield of DNA and its quality and 
new buffers were brought up. Finally, it is key to note that the protein yield for these 
mutations is characteristically low regardless. 
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Figure 8 The difference spectra of transient mutant rhodopsin Q28H (A), P23A 
(B), P23H (C) and T4K (D). Figures 1A-D are shown to magnify the peak and figure 
2A-D are to compare the peak size, the same samples are used for both. These 
mutants were transiently transfected into HEK293s cells using the calcium method 
and were rescued using 9-cis-retinal. The mutants were harvested and frozen and 
their spectra checked. The difference spectra was found by measuring the sample 
before and after photobleaching to locate the amount of rhodopsin present. A 12x 
diluted aliquot of the sample was used (100µl of 1,200 µl). The concentration of 
rhodopsin was calculated and is as follows; Q28H (A) 71.3 µg, P23A (B) 151 µg, 
P23H (C) 20.7 µg and T4K (D) 16 µg in 1.2 ml. 
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3.3 Ascertaining the presence of rhodopsin and its cleaved portions within 
samples  
The samples were analysed by western blot to show the presence of both full 
rhodopsin 40kDa and the truncated species, which as previously mentioned was found 
to be at roughly 27kDa (Tam & Moritz, 2007) making the corresponding species 
13kDa, however this species has not been identified on western blot analysis before.  
As can be seen from figure 9 there is rhodopsin present in P23A, P23H, WT-Rho and 
T4K samples. Figure 9.A shows a strong band at 40kDa (rhodopsin) for P23A non- 
rescued. The bands for P23A on figure 9.A seem to follow the same pattern, however 
the intensity of the bands for non-rescued seem to be higher than those of the rescued 
sample, it is likely that due to human error these samples were accidently switched. 
Figure 9.B shows a lower intensity for non-rescued P23A which would again support 
the theory that the rescued and non-rescued samples for P23A in figure 9.A may have 
been swapped. There is not a band at 28kDa for P23A in either figure 9.A or B however 
there does appear to be a band below 40kDa for none rescued and rescued P23A in 
figure 9.A it is possible that these bands are the truncated form and that if the sample 
had been left to run longer we may have seen the band at 27kDa. There are bands 
below that of 35kDa for the rescued P23A sample in figure 9.B and a weaker one at 
the same distance for non-rescued P23A, it is possible that the band in the non-
rescued sample is simply a shadow band but given such similarities in distance it is 
possibly the truncated rhodopsin. 
There is a clear difference in the bands seen for rescued and non-rescued P23H in 
figure 9.A and 9.B, this is to be expected. In figure 9.A we see rhodopsin present for 
both rescued and non-rescued and the appearance of a possible lower band for the 
rescued version, again we can’t be sure as the sample was not left to run long enough. 
In figure 9.B we only see clear bands for rhodopsin in one of the rescued versions, this 
sample however appears to have a clearly distinct band lower than that of the expected 
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40kDa for rhodopsin, this band cannot be considered a shadow band and so is very 
likely to be the truncated version. This supports the theory that the western blots do 
show the truncated species but were not run long enough to show a definitive weight. 
There were no bands produced by non-rescued T4K in figure 9.A there is however a 
slight band shown for the rescued sample. This weak band is likely due to low 
concentration of the sample used. Figure 9.B shows clear and distinctive bands for 
T4K clearly showing the presence of rhodopsin in both rescued and non-rescued 
forms. It is interesting to note the intensity of the final band for rescued T4K at around 
35kDa, this band is expressed weakly in the non-rescued version and is possibly the 
truncated form of rhodopsin. 
We can clearly see the three bands for the trimer dimer and monomer of rhodopsin for 
WT in both figure 9.A and B. There is no noticeable difference between the intensities 
of rescued and non-rescued WT in either figure 9A or B, this highlights the difference 
noted between the rescued and non-rescued versions of the mutant rhodopsin.  Using 
WT as a comparison we can  see that there are no bands lower than 40kda in any of 
the WT samples for figure 9.A, with only one band lower on figure 9.B non-rescued 
WT which is most likely a shadow band due to the fact there is no replication of this 
band on any of the other WT samples, again highlighting this difference in the mutant 
forms and thus providing more evidence that these lower bands are likely to be the 
truncated form of rhodopsin.  
If we compare the samples in figure 9.B we can see that the lower bands on T4K non-
rescued and rescued, P23A rescued and P23H rescued are all at the same hight lower 
than that of the shadow band located on WT non rescued sample. I believe this is 
proof that the truncated form is present in each of the mutated samples to some 
degree.  
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Figure 9 Western blots of WT and mutated rhodopsin samples harvested from 
transient transfection. The labels above each of the lanes indicates the type of 
mutation and the + and – is used to indicate if the sample was rescued. Those that 
have been rescued were treated with 9-cis-retinal l during transfection. These 
samples have been transfected using the calcium chloride protocol and were 
harvested in PBS. They were all treated with further retinal after harvest before 
testing via UV VIS Spectroscopy and then analysed further by western blots, using 
1D4 as the primary antibody. 
B 
kDa  WT-RHO  P23H  P23A  T4K  
Un-
transfected  
WT-RHO  kDa  P23A  P23H  T4K  
A 
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3.4 Attempted creation of A stable cell line for mutants P23A and P23H using 
Hek293s cells. 
A stable cell line was attempted to increase the efficacy of the project. The long 
transient transfection protocol meant that many hours were spent trying to produce the 
mutant protein. The separation protocols required a high concentration of protein to 
work well. The mutants P23A and P23H were chosen to create a stable cell line. 
A stable cell line for WT rhodopsin has been made before using the following papers 
(Reeves, et al., 2002) (Reeves, et al., 2002). Following much the same procedure, it 
was attempted to make P23H and P23A stable cell lines.  
  Following the methods section 2.2.8, we managed to transfect the cells so that 
they were able to produce the desired P23H/A mutant rhodopsin, had geneticin and 
blasticidin resistance and were inducible by tetracycline. This was made possible 
using the plasmid pACMV-tetO-P23H/A, which was produced following the methods 
used in (Reeves, et al., 2002). The HEk293 cells were transfected with the Tet operon 
repressor protein and blasticidin resistance. Those able to take up this plasmid were 
resistant to blasticidin which was the first marker used, followed by geneticine testing 
and finally the cells were induced using tetracycline. It is possible that at any of these 
stages of selection, the process had not been fully successful as any cells allowed to 
multiply without the resistance for these antibiotics couldn’t go on to form the stable 
cell line or produced the desired protein.  
 Figure 10, shows the dot blots that were created using samples from the stable cell 
line experiment. Figure 10.A shows the outcomes from the P23H experiment, and 
figure 10.B shows those of the P23A experiment, each pair of dots represents a 
different colony collected, for each mutant we tested 11 samples. The positive and 
negative symbols represent those induced by tetracyclin and those not induced 
respectively. Thus we should get higher intensity dots for the positive columns. The 
samples are diluted as we move down the coloumn, this means that the dot blots 
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should  show a gradual decrease in intensity as the protein becomes more and more 
diluted. We also have a positive and negative control depictied with PC and NC 
respectively. The PC is the rescued T4K sample used for figure 9.B and the NC is a 
sample of harvested un-transfected cells. 
Figure 10.A shows no positive result with the negative control expressing with the 
same intensity of the other samples. We can clearly see an increase in intensity of the 
dots shown for the positive control which have not been duplicated in any of the other 
samples. Leading to the conclusion that none of the P23H samples contained protein 
and so we failed to produce a stable cell line for P23H.  
Figure 10.B has one high intensity dot, on the last row of the second column, given 
that it is the final dot of this column and that the intensity should decrease as we move 
down the dots it is interesting that this seems to have so much protein present. When 
we compare this dot to the positive and negative controls we can see that the intensity 
of the dot in the second column mimics that of the positive control. The other dots in 
figure 10.B match that of the negative control, showing that no protein was detected 
in the other samples. This dot blot would need to be repeated to be certain of the 
presence of protein.  
It is important to note that there is a possibility that the experiment was 
successful but due to poor induction of the cells it cannot be seen clearly on the dot 
blot. This could have been tested by bringing up the cells again until confluent and 
inducing them, running another western blot analysis, and seeing if this made a 
difference. There was however time sensitivity issue with this project and it was 
thought best to not continue testing as we had to complete the two rounds of 
immunoaffinity chromatography. 
 
 
62 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10 A dot blot of colonies collected from stable cell line transfection of 
P23H and P23A. This dot blot contains samples from different colonies of the 
attempted stable cell line P23H (A) and P23A (B) mutant type rhodopsin, both with 
induction (+) and without induction (-) to show the expression of the mutant 
rhodopsin. These cells were brought up with blasticidin resistance, the cells were 
then transiently transfected using the described Teto- mutant type plasmids. The 
cells were then tested for Geneticin resistance and left to form colonies. These 
colonies were then isolated before being re-plated into 24 well plates,  split thrice 
upon confluence, for freeze down, induction and non-induction. The induced and 
non-induced samples were transferred to mirocentrifuge tubes and spun for storage 
at -20. On the far right are the positive and negative controls which were previously 
made up from transfection protocols, the PC (positive control) is the T4K mutant 
which had on a pervious western blot shown good expression, the NC (negative 
control) is of an un-transfected cell which also underwent the same procedure as 
the positive control without the addition of DNA. The Dot blot was carried out as 
described fully in the methods section.  
A  
A  B 
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Chapter 4) Results of  purification of truncated rhodopsin   
The main objective of this study was to isolate and analyse the truncated forms of 
mutated rhodopsin. As previously established in multiple studies and explained in the 
literature review, rhodopsin with mutations in the N-terminus can be pharmaceutically 
rescued using the chromophore, vitamin A derivative; 11-cis-retinal. This rescue 
however is believed to lead to the protein being cleaved by proteasomes at the N 
terminus. To prove this, two different forms of immunoaffinity chromatography were 
utilised, this was done with the hope of separating out the desired truncated rhodopsin. 
As discussed, it is our belief and that of others that the P23H mutant truncates in-order 
to stabilise the rhodopsin protein so that it can be trafficked through-out the cell (Tam 
& Moritz, 2007). The mutants chosen are all located within the N-terminus to try to 
show that all mutants located in the N-terminus followed this pathology.  
Chromatography is a method of separating out a desired protein. The initial step is to 
set up a method by which the protein can be identified and isolated, there are multiple 
forms of chromatography which utilise different properties of the protein for instance 
Ph level, charges and size; in the case of affinity chromatography the aim is to bind to 
a specific ligand. Affinity chromatography is a well-established method which exploits 
biological-like interactions of the desired protein to isolate it out of a liquid.  
After finding a suitable ligand it is chemically immobilized onto a stable support, this 
will allow the protein when bound to stay within the affinity column rather than to wash 
through still bound. The ligand now bound to the support is normally suspended in a 
liquid and this solution is known as a slurry. The protein mixture is made up with the 
specific conditions so as to increase binding affinity to the ligand. The slurry is then 
added to the mixture of proteins and is incubated often at specific temperatures and 
on a rotator to mix end over end to increase binding. Once the mixture has been left 
for the appropriate amount of time the mix is poured into the affinity column and the 
liquid is allowed to be run through. The proteins are then washed a number of times 
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dependent on the size of proteins or the size of the column to ensure only the bound 
protein is remaining. An elution buffer is made up which usually contains a different 
set of conditions which will loosen or dissociate the desired protein from the ligand, or 
in some cases contain a competing protein which will bind instead to the ligand. The 
result is the purified protein is eluted off with minimal to no contaminates. This is clearly 
represented in figure 11, which shows the general system used for separating out 
proteins using affinity chromatography (Scientific, N.D).   
 
Figure 11) The basic structure of affinity chromatography. I) Shows the column, and 
the mixture of proteins. II) shows the solution being added to the beads and being allowed 
to flow through the column at this point the undesired proteins are beginning to flow 
through. IV) the wash is added to the column to remove the rest of the unwanted 
contaminates. V) The wash is allowed to flow through removing the remaining unwanted 
proteins, leaving only the bound desired proteins. VI) The elutant is added and it competes 
with the proteins to bind the lectins which are attached to the beads. VII) The elutant is 
then run through allowing for the separation of the desired protein.  
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In this case the protein we wish to separate is rhodopsin. It is hypothesised that  11-
cis-retinal in the ER allows for the pharmaceutical rescue of the mutated rhodopsin 
allowing the protein to fold and leave the ER. It has been shown that ADRP rhodopsin 
cleaves at the N-terminal cap to increase stability, the identification of truncated P23H 
rhodopsin has already occurred, however as of yet we know little of the fractions of 
rhodopsin how they occur and what protein kinase cleaves them (Tam & Moritz, 2007).  
To answer these questions, I wanted to isolate the different variations of this cleaved 
form of rhodopsin, assuming at the time that the truncated mutated rhodopsin will have 
lost its glycosylation sites. I have utilised two forms of Immunoaffinity chromatography, 
one which binds to the TETSQVAPA sequence located on the C-terminus of rhodopsin 
(1D4-Rho) and the second Con-A which binds to mannose sequences on the N 
terminal Cap. The immunoaffinity chromatography separations were run 
consequtively. The first separation purifys the sample, 1D4 as mentioned attaches to 
the carboxylic end of the protein. This means that in the elutions form this separation  
should comprise of all rhodopsin with a c terminus, leaving us with the truncated form 
and the full rhodopsin. The second separation will only bind to those with an N 
terminus, given that we believe this has been cleaved off the truncated form, the 
elution for this column should only contain full rhodopsin. The wash through and initial 
run through of the sample should then contain all the truncated rhodopsin. The basic 
flow through of how we intend to separate out the truncated mutant can be seen in 
figure 12. 
These were both originally tested using purified ROS Rhodopsin, thus we could asses 
if the buffers or apparatus used caused degrading of the protein. It was however 
assumed that regardless of the success of these preliminary tests that the recombinant 
WT and the recombinant mutants would be harder to isolate.  
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Figure 12 The basic flow diagram of the method used to isolate out the 
truncated mutant rhodopsin. I) The mixture of proteins with the C terminal in red 
and the N terminal in green, the 1D4 beads within the column and an image of the 
rhodopsin attached to the 1D4 beads on the C terminus. II) The rhodopsin now 
bound and the prepared wash. III) The flow through with the wash now added to 
the column and the elutant prepared. IV) The collected wash and the contaminants 
that came with it. V) The elution containing all separated rhodopsin. VI) The Con A 
beads prepared in the column and an image of the Con A sepharose beads bound 
to the N terminal end of the rhodopsin. VII) The 1D4 elution added to the column 
and the prepared wash. VIII) The flow through including some of the truncated 
rhodopsin mutants with no N terminus, the wash added to the column and the 
prepared elutant. IX) Shows the collected wash with more of the unbound truncated 
mutant rhodopsin and the elutant added to the column. X) The elutant containing 
all the full rhodopsin species, with the con A beads in the column  
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4.1 1D4 separation protocol  
The 1D4-sepharose bead separation protocol has been widely analysed and thus the 
protocol for this has been well established, and was described previously in the 
methods. A preliminary result was taken using purified ROS rhodopsin to verify the 
efficiency of the protocol.  
Purified ROS rhodopsin was used to run the first purification protocol as a control to 
ensure highest efficiency possible and to make any changes to the protocol prior to 
using the cell extract samples gained. Prior to purification, UV Vis spectroscopy was 
run on the ROS rhodopsin to identify the concentration of the sample. This protocol 
was followed slightly differently from the other UV Vis spectroscopy as the sample 
used did not need to be lysed, thus 20 µl of the sample was diluted by PBS into a 
500µl sample for UV spectroscopy. This ROS rhodopsin was formed with 11--cis-
retinal rather than 9-cis-retinal so the peak is identified at 500nm, not at 490nm. The 
UV Spectra from this experiment can be seen in figure 14A-C, which clearly show the 
rhodopsin peak.  
In Figure 14 A and B we can clearly see the difference between the dark and bleached 
spectra, with a much neater shift of the 500nm peak than in the transient transfection 
UV Spectra seen for WT in figure 7.A. The calculations for the spectra were conducted 
as previously explained and the purification protocol was then run. The output for the 
purification protocol can be seen below in figure 14.D, the protocol was run using 100 
µg of the sample.  
Figure 14.D shows the elutions taken from the purification protocol, to see the purity 
of this sample the 280/500nm ratio was calculated. The absorbance at 280nm was 
0.206392 and the absorbance at 500nm was 0.115069, thus the ration of purity was: 
0.55. An ideal purity ratio is around 0.6.  
The concentration of rhodopsin from the UV Vis spectra was calculated as follows. 
68 
 
For the calculations assume that the total amount in the sample is 100 µl. 20 µl is 
added to the 500µl sample a 5X dilution.  
The highest value is at 501nm absorbance 0.073887 
0.073887/40600 x1 = 1.819x 10 -6 
1.819x 10 -6 x 40,000 x 1,000 = 72.795µg/ml 
72.795µg/ml  2 = 36.39µg per 500µl 
36.39 x 5 = 181.9876µg in the final sample. 
An aliquot of roughly 150 µg of this was then taken to perform the separation protocol 
as seen in figure (14.D). The concentration of the elution was then calculated 
Elution 1 absorbance at 500nm – 0.115069 leads to 113.3 µg in 500 µl 
Elution 2 absorbance at 500nm – 0.031807 leads to 31.3 µg in 500 µl 
Elution 3 absorbance at 500nm – 0.008544 leads to 8.4 µg in 500 µl 
Elution 4 absorbance at 500nm – 0.005 leads to 5 µg in 500 µl 
The total rhodopsin eluted was 158 µg, this would indicate that there was a problem 
with calculations which could have been avoided by double checking concentration 
prior to elution. It is also possible that the calculations aren’t exact as checking 
concentration in this manner is not specific, if this is to be believed then protocol 
efficacy is near 100%. 
 
 
69 
 
 
 
 
 
 
 
 
 
Figure 13 (A-C) WT ROS rhodopsin control absorbance spectra and (D) 
absorbance spectra of the 1D4 sepharose separation elutions from this 
sample. The UV vis spectra obtained using purified ROS rhodopsin. A) ROS 
rhodopsin was diluted using PBS: 20 µl into 500 µl to obtain the dark and 
photobleached UV vis spectra, the rhodopsin present can be clearly seen by the 
peak at 500nm and the metarhodopsin II state can be seen at 380nm. B) A close 
up of the graph seen in A to show the difference between dark and photobleached 
state. C) the difference spectra obtained from figure 14 A by taking the bleached 
spectra away from the dark spectra to calculate the exact amount of rhodopsin 
present: 72.795 µg. D) Once the concentration of rhodopsin was ascertained a 
small aliquot of this was then used for 1D4 –sepharose separation, the elutions are 
taken in order 1, 2,3 and 4.  
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Figure 14 A-D are the elution fractions of the 1D4-sepharose separation protocol of 
the mutant rhodopsin. Figure 15 A-D are the results from the elution fractions of figure 
14 A-D, showing fractions against absorbance at 490nm, presenting clearly the flow 
of rhodopsin through the separation protocol.   
Figure 14.A (Q28H) shows a clear peak on elution 1 and shows much smaller broader 
peaks for elution 2 and 3. This can also be seen in figure 15. A which shows a high 
peak at the first fraction (elution 1) and then shows a small secondary peak at fraction 
4 (elution 3). There is a consistent level of rhodopsin showing throughout the 
separation, with the wash fraction showing higher levels of rhodopsin than the fractions 
of elution 3 and 4. This could mean that not all rhodopsin was bound due to 1D4-
sepharose beads leading to washing out of the rhodopsin. The consistent high 
absorbance could also be due to inaccurate blanking or overheating of the UV/VIS 
chromatography spectrometer. The purity ratio was calculated at: 0.36 and the 
concentration of rhodopsin was 16.2µg. 
Figure 14 B (P23A) again shows a clear peak for the first elution with a secondary 
smaller peak for elution 2. The purity ratio was calculated at 0.26, this is significantly 
lower than desired. Figure 15. B emphases the peak at elution 1 but does not highlight 
the peak that can be seen at elution 2. The wash fraction is below zero which again 
could be indicative of blanking error or machine failure. The wash fraction has lower 
absorbance than that of fractions 4 and 5 indicating low if not no concentration of 
rhodopsin present in the wash. This means that complete binding of rhodopsin 
occurred. There is also very little rhodopsin recorded in the elution 2 with no rhodopsin 
present in either elution 3 or 4, meaning that over 80% of rhodopsin eluted  was eluted 
in the first elution.  
 Figure 14.C (T4K) shows a clear peak at 490 nm and a smaller and much broader 
peak present in elution 2. The concentration of rhodopsin in the first elution was 
calculated at 7µg with a purity ratio of 0.24. Figure 15 C allows for a clearer image of 
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this broader peak at elution 2, while highlighting the peak at elution 1. Interestingly we 
can see an increase of rhodopsin present in the fourth elution which when looking at 
figure 14.C is only slightly present but not shown as a peak. This result may have been 
due to elution buffer not being fully run through and left in the separation column 
increasing the concentration of the final elution. It may also simply be a machine error 
due to overheating.  
Finally figure 14.D (P23H) shows a broader peak at 490nm and what appears to be a 
steaper increase to 280nm, this is not noticed in the other ADRP rhodopsin samples. 
This increase may be due to failure of the 1D4 sepharose coloumn to separate the 
rhodopsin from its contaminates. It is possible that for this sample more washes 
needed to be completed due to excess retinal. As the concentration of retinal added 
to the samples at transfection remains the same, if the concentration of rhodopsin 
harvested is lower the ratio of retinal to rhodopsin will change, and thus more washes 
will be needed to remove this excess. This could also explain why the purity ratio of 
elution 1 is 0.17, much lower than the other mutants tested. The other elution fractions 
however do not show this increase in 280nm, so it is possible that this result is simply 
an outlier. Figure 15.D highlights the wash sample, which is below 0, this again may 
be due to machine error or blanking issues, if we were to 0 this result we would see 
an increase in rhodopsin present throughout the rest of the fractions. We again notice 
the slight increase of rhodopsin showing in the final fraction.  
Having a higher purity ratio for Q28H again is unexpected as previously explained in 
section 3.2, Q28H should show a lower purity ratio than P23A. It is likely that the quality 
of the DNA used for transfection of Q28H was simply higher than that used for P23A. 
This would explain the difference of Q28H to P23A while also explaining why T4K and 
P23A consistently have similar purity ratios as found in previous works.  
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Overall we can see from figure 15 that P23A had the best flow of rhodopsin, despite 
having a slightly lower purity ratio and concentration than that of Q28H. There 
appeared to be a constant flow of rhodopsin from Q28H which would indicate poor 
binding or a poor 1D4 slurry to rhodopsin ratio. It is interesting to note that the 1D4 
separation appeared to work best for those more stable mutants P23A and T4K, with 
Q28H being an outlier.  
We could improve on the elution process of the 1D4 separation by increasing the 
percentage of rhodopsin obtained in the 1st elution. The best way to do this would be 
to increase the amount of competing ligand in the elution or leaving the competing 
ligand longer to bind. The higher concentration obtained here will allow for a higher 
concentration to be used in rho-con A-sepharose separation and thus leading to a high 
concentration of truncated rhodopsin obtained. We must also increase the purity ratios; 
samples may have been affected by an increase of retinal contaminates. There was a 
high amount of retinal present in the mutant samples due to retinal being added before 
and after transfection. This meant that there needed to be an increase in the amount 
of washes compared to that of the purified ROS rhodopsin that was used to test the 
protocol. It is possible that more washes were needed and excess retinal remained as 
a contaminant which would of lead to an increase of absorbance at 280nm and thus 
poor purification ratios.  
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Figure 14 The elution of 1D4-sepharose separation protocol for the 
recombinant mutant rhodopsin. The rhodopsin was obtained via transient 
transfection and the initial concentrations were found using UV vis spectroscopy. 
The rhodopsin was then prepared for 1D4 separation as seen in the methods 
section 2.3.1, once bound they were washed of excess retinal and then eluted off. 
A, B, C and D show Q28H, P23A, T4K and P23H respectively. The absorbance at 
490nm shows the rhodopsin present. 
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Figure 15 A chromatogram of rho-1D4-separation column of ADRP rhodopsin 
mutants. The rho-1D4-sepharose separation was conducted on previously 
harvested ADRP rhodopsin mutants, the rhodopsin was then bound to the 1D4-
sepharose beads before being washed and finally eluted using competing ligand 
rho-1D4 peptide. The chromatogram shows the absorbance at 490nm for a wash 
sample and each of the elution fractions obtained from 1D4-sepharose separation, 
showing the flow of rhodopsin over the course of the separation. The full UV/VIS 
spectra of these elution fractions can be seen in figure 14. The fractions are 1- 
Wash, 2- elution 1, 3- elution 2, 4 -elution 3 and 5 – elution 4. The mutants are 
P23A, P23H, T4K and Q28H showing as A,B,C and D respectively.  
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4.2 Con-A separation protocol  
Concanavalin A or Con A works by binding onto the Glycan moieties left behind by 
glycosylation. It was found that non reducing α-glucopyranosyl, α-mannopyranosyl or 
α-fructofuranosyl residues can be precipitated by concanavalin A (Ogata, et al., 1975). 
The oligosaccharide chains on rhodopsin are predominantly GlcNAc3Man3 with some 
containing Man4 and Man5 and have been shown in WT to bind to Con A as a method 
of separation (Shichi, et al., 1980). It is important to note that  the four mutations that 
were used during this experiment; Q28H, T4K and P23A/H have all been proven to 
have effects on the glycosylation of rhodopsin (Behnen, et al., 2018) (Chen, 2014) 
(Sakami, 2011). This could cause problems as in order to separate out the truncated 
species of the mutated rhodopsin, the N terminus with completed glycosylation and 
thus glycan moieties intact must bind to the con A, if there are problems with this 
binding it could lead to contamination of the elution. 
The Con A protocol was taken from multiple difference papers and then altered to 
increase efficiency. Originally focus was on the increasing % of binding of rhodopsin. 
This included analysing the time needed and the suitable amount of ions needed to 
create an environment that the protein could bind to the beads most efficiently. It was 
found that roughly 2.5 hours is the best amount of time. We determined that ion 
concentration made very little difference by excluding ions from the sample, or the 
wash buffer and then having them present in both as a control. The focus then fell 
upon the elution buffer, working from the original papers we had a much lower sugar 
concentration in the initial protocol than was necessary. Increasing the ion 
concentration was attempted at first but to no avail, the salt concentration was then 
increased again no real difference was noted, finally there was an increase of the 
sugar concentration from 0.15M, to 0.3M this increased the rhodopsin concentration 
in the mutants. It should be noted that the amendments to the protocol were all done 
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using purified ROS rhodopsin meaning that for harvested rhodopsin from cell extracts 
this protocol may need to altered again. 
Figure 16 shows the mutant con A-sepharose wash and elution fractions as well as 
that of WT. we can clearly see that figure 15.E (WT) has successfully eluted out 
rhodopsin which means that it is possible to run both separation protocols on a 
recombinant rhodopsin and get the full rhodopsin eluted.  Figure 16 A-D show the 
mutant rhodopsin, we can see that the washes from each shown in purple appear to 
drop off at the 280nm mark whereas the elution fractions seem to increase at the 
280nm mark. This stark difference could be due to the difference in buffer content and 
poor blanking. There appears to be no peaks showing at 490nm, we can see this more 
clearly from figure 17 which shows a zoomed in graph of figure 16. This is due to the 
low quantities of rhodopsin being tested, in order to show a clear peak, the difference 
spectra should be shown. The difference spectra however was never measured and 
the samples were thrown away before this could be rectified. The low volumes of 
rhodopsin are to be expected after two separation columns.  
Figure 17 D seems to show a slight change in the incline of the wash fraction at roughly 
490nm. The wash fraction is producing a higher level of absorbance than the elution 
sample, this could potentially mean there is more rhodopsin present in the wash 
fraction. Given that the truncated rhodopsin mutant would not bind to the Con A it 
would be fractioned off either at the flow through or the wash, thus we could be seeing 
rhodopsin here. This agrees with previous work which found that P23H showed the 
highest level of truncated species, which could be why this has not been replicated in 
the other mutants (Krebs, et al., 2010). It should be noted from figure 16. D that there 
is a dip for the wash at 280nm, which would indicate a lack of protein. It is also possible 
that due to the changing buffers, the blanks for these washes were not accurate which 
would have skewed the data.    
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Figure 16 The UV spectra of WT and ADRP rhodopsin obtained from the wash 
and elution fractions of Con A-Sepharose separation protocol. The samples 
were first purified using the protocol 1D4-sepharose separation. The samples were 
then bound to Con A Sepharose beads, subjected to washing before an elution 
buffer containing Methyl α-D-Mannopyranoside was added which competed with 
the rhodopsin allowing  the full ADRP rhodopsin mutant to be eluted off. The 
protocol was preformed on the first Elution of 1D4-sepharose separation of ADRP 
rhodopsin mutants seen in Figure 14 and 15. The mutants are in the following order; 
A – Q28H , B-P23A, c WT D- P23H E- T4K. 
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Figure 17 The UV spectra of ADRP rhodopsin obtained from the wash and 
elution fractions of Con A-Sepharose separation protocol. The samples were 
first purified using the protocol 1D4-sepharose separation. The samples were then 
bound to Con A Sepharose beads, subjected to washing before an elution buffer 
containing Methyl α-D-Mannopyranoside was added which competed with the 
rhodopsin allowing  the full ADRP rhodopsin mutant to be eluted off. The protocol 
was preformed on the first Elution of 1D4 sepharose separation of ADRP rhodopsin 
mutants seen in Figure 14 and 15. The mutants are in the following order; A – 
Q28H , B-P23A, C-T4K D- P23H. 
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Figure 18 shows the western blot analysis of the separation protocols of P23A against 
WT separation protocols. We expect that from the 1D4 protocol that we will see 
minimal rhodopsin present in the wash sample, minimal rhodopsin in after binding 
sample and  high intensity bands showing in the first elution of 1D4 becoming less 
intense for the second elution. From figure 18 we do see similar results to what we 
expected. The bands for the first elution are more intense than that seen in the second 
elution and more intense than the wash and binding samples. We do see rhodopsin 
present in the binding sample, this means that the rhodopsin in the sample had not 
fully bound. This could be due as previously stated to low concentrations of 1D4-
sephraose beads or low binding time. The rhodopsin is also coming through in the 
wash albeit showing less intense bands, this again is due to binding issues. The most 
important point to notice is the lower band, which is showing clearly in the first elution, 
this means that we are continuing to isolate both the full mutated rhodopsin and the 
truncated species. We can see this lower band depicting the truncated species in all 
the elution fractions but not in the wash or binding. The elution fractions show a very 
clear decrease in intensity of the bands directly reflecting the lower concentration of 
rhodopsin eluted as we continue through the separation.  
From the Con A-sepharose separation we expected to see clear bands showing the 
truncated species in the after bind and wash samples, we expected to have high 
intensity bands for rhodopsin in the elution with no band for the truncated species 
present. In figure 18 we can see P23A original sample has a clear 40kDa band for 
rhodopsin and lower bands indicating the presence of the truncated form. After binding 
1D4 and wash 1D4 do not show the 28kDa band meaning there is no truncated 
rhodopsin present. There are bands at 40kD showing full mutated rhodopsin indicating 
loss of rhodopsin throughout binding. This could be due to not enough time being left 
for the binding or the binding environment was wrong. Full P23A rhodopsin was eluted 
off, showing that it is possible to separate the rhodopsin mutants in this manner, there 
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is also an increase in the intensity of the bands for the elution compared with those of 
the was and after binding flow through, meaning that majority of rhodopsin was bound 
and eluted as intended.   
This protocol requires cold temperatures and no light exposure to ensure that the 
mutants are well maintained. When repeating this experiment more measures such as 
air con should be utilised to control these variables. The separation also requires an 
increase in rhodopsin concentrations, this means increasing concentration at the 1D4-
sepharose separation so that this filters down. The binding efficiency of Con A to 
mutated rhodopsin should be increased, this can be done by testing the environment 
of the solubilisation buffer and the binding times. This protocol was improved using 
purified ROS rhodopsin and didn’t take into account the contaminates and reduced 
stability of the rhodopsin mutants. This will need to be adjusted in order to isolate the 
P23A truncated species.  
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Figure 18 A western blot of the bindings, washes and elutions of both the 1D4 
-sepharose separation and the con A-sepharose separation. The 
 each aims to separate out the rhodopsin by binding either to the C terminus or the 
N terminus of rhodopsin. Each of the separation protocols and the mutant used is 
clearly shown at the top. The trimer, dimer and monomer band for rhodopsin is 
clearly indicated. The lower bands are likely to indicate the truncated rhodopsin. 
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Future work  
 
Our aim was to increase knowledge of the pathology of retinitis pigmentosa caused by 
ADRP mutations with the intention of opening pathways for new treatments. We were 
successful in the first part of our experiments; finding a way to isolate the ADRP 
truncated species. We proved it is possible to obtain a reasonable amount of rhodopsin 
after two separation columns using the purified ROS rhodopsin and obtain full P23A 
rhodopsin after two separation columns. There remain some issues with isolating the 
truncated species of P23A rhodopsin, which could be for several reasons and 
modification of the Con A-sepharose immunoaffinity column is needed. The ability to 
isolate both full and truncated mutated rhodopsin species will enable others to start 
testing on these separated truncated species to better understand the disease we are 
fighting.  
To prefect the Con A-Sepharose column, the experiment will need to be repeated 
using higher quantities of ADRP rhodopsin, which will enable us to ascertain whether 
there was simply was not enough of the truncated species present to show on the 
western blot. The Con A to rhodopsin ratio will need to be adjusted given that 
rhodopsin is present in the wash, meaning that not all the rhodopsin was bound to Con 
A. This means that any separated truncated species will be contaminated.  
Having isolated the truncated form of rhodopsin we must now look at its biochemical 
characterisations, effecting experiments to discover its; thermal stability, 
photobleaching properties, and metarhodopsin II decay formation. Investigations into 
these characterisations have all been previously run to compare the outcomes of 
ADPR mutations to those of the WT, to ascertain the degree of misfolding. In previous 
papers it has been found that ADRP mutations have behaved unexpectedly in these 
experiments. The Metarhodopsin II decay kinetics of ADRP mutants were found to be 
made of both fast and slow components compared with the single component of WT. 
I expect that re-running these experiments (having isolated the truncated species) will 
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shed more light on why this is. I would propose running in parallel experiments with 
WT, the truncated ADRP species, and the full ADRP species, of each mutation.  
The natural progression would be to ascertain which of the protein kinases is likely to 
have caused the truncation of the ADPR mutants. We can select likely kinase inhibitors 
and test them in batches, running western blot analysis to determine the lack of the 
lower band located at 28Kda. The rhodopsin harvested will need to undergo 
biochemical characterisation to learn the degree of misfolding and then to compare 
this to WT rhodopsin, and the mutated rhodopsin, without kinase inhibitor involvement. 
This permit understanding of the decrease or increase of stability that is offered by 
blocking the truncation of the N terminus. If the stability is reaching that of the WT 
rhodopsin we can consider this a route to possible future treatments for retinitis 
pigmentosa. 
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Conclusion  
Our aim was to increase understanding of the pathology of retinitis pigmentosa caused 
by autosomal dominant mutations located in the N terminus. We planned to do this by 
separating the truncated species of the ADRP mutated rhodopsin from the full species 
of ADRP mutated rhodopsin using two forms of immunoaffinity chromatography. 
These are Rho-1D4-sepharose which binds to the TETSQVAPA sequence on the C 
terminus, and Con A – Sepharose which binds to the glycan moieties located on the 
N terminus. The truncation removes the glycosylation sites and thus the ability of the 
truncated species to bind to Con A. The intention was to preform biochemical 
characterization, preforming experiments on, thermal stability, metarhodopsin II decay, 
and photobleaching properties.  
We managed to obtain high concentrations of ADRP rhodopsin from transient 
transfection with 9-cis-retinal rescue. The results of these confirmed the degree of 
misfolding found in previous papers. Figure 8 showing P23A to have the highest 
concentration of rhodopsin, and one of the highest purity ratios. The purity ratio is an 
approximate reflection of the degree of misfolding. Further to this, and confirming 
previous work, T4K and P23A continued to show similar purity ratios throughout the 
experiments, meaning they have a similar degree of misfolding (Krebs, et al., 2010) 
(Opefi, et al., 2013). We found one outlier in Q28H which consistently had a higher 
purity ratio, and concentration levels that matched those of P23A. We believe this 
anomaly is due to the quality of the DNA used at transfection being higher than that of 
any of the other three mutants, which all behaved as expected.  
The 1D4-sepharose separation performed well. We managed to elute rhodopsin from 
each of the four ADRP rhodopsin mutants. We also greatly increased the purity ratio. 
Samples in figure 8 produced the following ratios; 0.07 Q28H, 0.05 T4k, 0.05 P23A, 
and 0.004 P23H, compared favourably with the outcome of the separation protocol in 
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figure 14, which produced the following; 0.36 Q28H, 0.26 P23A, 0.24 T4k, and 0.17 
P23H, showing a marked difference with the Q28H purity ratio increasing five fold.  
The Con A sepharose separations however delivered varied results. Figure 13, 
depicting the Con A – sepharose separation of purified ROS rhodopsin, shows clear 
peaks at 500 nm for the elution fractions, with just over 70% of rhodopsin eluted in the 
first elution. This means we created a successful protocol isolating rhodopsin using 
Con A-sepharose. Figure 17 and 16 do not show clear peaks located at 490nm, which 
leads to the assumption that no rhodopsin protein was present. The difference spectra 
is likely to show a much clearer peak at 490nm, however the bleached spectra was 
not taken and could not be taken as the samples had already been discardedy. If the 
experiment was to be repeated it would be necessary to obtain the difference spectra 
to help identify the rhodopsin peaks of these samples. The current lack of peaks in 
figure 16 and 17 is due to low levels of rhodopsin as would be expected in the event 
of a secondary separation column. Poor starting concentrations were also instrumental 
in the inability to identify peaks; having gone through two separation protocols some 
of the protein was lost in various phases and thus lowered the final concentration of 
rhodopsin yielded. Figure 18 shows we managed to isolate full P23A rhodopsin but 
were unable to isolate the P23A truncated species. The band for full P23A rhodopsin, 
40kDa, was present in the “wash”, and “after binding” lanes of Con A separation, this 
means that if the truncated species had been present it would not have isolated. This 
is due to the poor binding of the P23A mutated rhodopsin to Con A. To increase this 
binding, further experiments will be needed. These will include investigating the effect 
of changing, the binding buffer, the concentration of Con A Sepharose, and the binding 
time. The different outcome of the protocol despite good results form the purified ROS 
rhodopsin, is likely due to the instability of the mutant. Finally we should mention that 
it is possible that Con A binding to the mutated rhodopsin differs from that of the WT 
rhodopsin due to the fact that Con A binds to the glycan moieties located at the 
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glycosylation sites and these N terminal mutations have been shown to effect the 
glycosylation sites. However, it is important to note that there is clearly binding of the 
mutant occurring or the rhodopsin would not have appeared in all the samples, if the 
protein had not bound it would have washed through prior to the elution.  
As with much research multiple complications meant that we were not able to achieve 
the totality of our original aim, which was to separate the species of mutated rhodopsin, 
to enable their biochemical characterisation and thus further understanding of  retinitis 
pigmentosa. The research was not without success for instance we managed to 
separate out the fully formed rhodopsin and our results clearly indicate that it is 
possible to obtain a truncated form of rhodopsin.  
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Appendix  
1.1 Western blots  and SDS page Analysis  
Media preparation 
 4x running buffer  
• 18.5g Tris- HCL ph8.8  
• 100ml RO water 
• Filter sterilised, kept dark at 4°C 
4X stacking buffer  
• 3g Tris- HCL pH6.8 
• 50ml RO water  
• Filter sterilised, kept dark at 4°C 
1 X Tank buffer  
• 0.251M Tris 
• 0.192 M glycine 
• 0.1% SDS 
• Made up in RO water 
4X Loading buffer 
• 0.25M Tris-HCL (ph 6.8) 
• 8% SDS 
• 40% Glycerol  
• 0.4M DTT 
• 0.04% bromophenol blue  
1X Transfer buffer  
• 0.25M Tris-HCL 
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• 0.192M Glycine  
• 0.1% SDS 
• 20% Methanol  
• Made up in Ro water 
Blocking Buffer 
• 10% skim powdered milk  
• 0.1% Tween -20 (sigma P-5927) 
• 0.1% NaN3 
• Made up in 1X PBS 
Wash Buffer  
• 0.5% Skim powered milk 
• 0.1% Triton X-100(sigma-x100) 
• Made up in 1XPBS 
ECL  
• 10ml of 0.1M Tris-HCL 
• 50µl of 0.25M Luminol (sigma 09253) 
• 22µl of 0.1M coumaric acid (sigma C-9008) 
• 3µL of 30% H202 
Primary antibody  
• 0.5% gwlatine (sigma G8150 type A) 
• 0.25% BSA (sigma 85040-C) 
• 0.1M K-Po4 –Ph 7.4 
• 10µg/ml 1D4 antibody 
•  
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Table 1) The procedure for making Running/resolving gel for 
use in Western blots and SDS page analysis  
Reagents 10% (0.75mm) gel 
Acrylamide/Bis-acrymlamide, 
30% solution  
2.65ml 
4X running gel buffer 2.0 ml 
10% SDS 0.08 ml 
MiliQ water 3.2 ml 
10% ammonium persulfate 
(APS) fresh on the day 
0.08ml 
*TEMED 0.004ml 
Final volume 8 ml  
 
 
 
 
Table 2) The procedure for making Stacking gel for use in 
Western blots and SDS page analysis 
Reagents Amont for 4.5ml volume 
Acrylamide/Bis-acrymlamide, 
30% solution  
0.7 ml 
4X running gel buffer 1.13 ml 
10% SDS 0.06 ml 
MiliQ water 2.7 ml 
10% ammonium persulfate 
(APS) fresh on the day 
0.06ml 
*TEMED 0.004ml 
Final volume 4.5 ml  
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1.12UV spectroscopy  
 
Buffer A – Solubilisation buffer  
1% DDM 
0.5mM PMSF 
In PBS  
 
1.2 Dot blots  
 
Buffer A – Solubilisation buffer  
  
        Made up in 1x PBS 
Buffer B – Dilution solution  
 
       1x PBS 
Buffer C – wash buffer  
(Buffer B + 10x triton)  
Buffer D – Blocking Buffer  
  
Made up in 1x PBS 
 
 
1% DDM 
0.1% DDM 
10% Skim Powdered Milk  
0.1% Tween 20  
0.1% NaN3 
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